{
  "metadata": {
    "version": "2.0.0",
    "created": "2026-02-24",
    "purpose": "RCMXT calibration benchmark — 3 domains x 50 claims for Paper 1 (Nature Methods)",
    "researcher": "JangKeun Kim, Weill Cornell Medicine",
    "total_claims": 150,
    "distribution": {
      "spaceflight_biology": 50,
      "cancer_genomics": 50,
      "neuroscience": 50
    },
    "difficulty_distribution": {
      "easy": "~30% per domain",
      "medium": "~40% per domain",
      "hard": "~30% per domain"
    },
    "scoring_dimensions": {
      "R": "Reproducibility — fraction of independent replications (0.0-1.0)",
      "C": "Condition Specificity — how context-dependent (1.0 = broadly generalizable)",
      "M": "Methodological Robustness — study design quality (0.0-1.0)",
      "X": "Cross-Omics concordance — agreement across omics layers (null if single-omics)",
      "T": "Temporal Stability — consistency over time (0.0-1.0)"
    },
    "supersedes": "rcmxt_50_claims.json (v1.0.0)",
    "provenance": {
      "score_source": "ai_generated",
      "score_method": "Expected scores were generated by Claude (Opus) based on literature-grounded rationales. Each claim includes a rationale field explaining the scoring basis with specific citations.",
      "validation_status": "pending_expert_review",
      "recommended_use": "Calibration benchmarks for relative scoring consistency (inter-claim ranking), NOT absolute ground truth. Suitable for: variance analysis, regression testing, domain-coverage verification.",
      "limitations": [
        "Scores reflect AI assessment, not expert consensus panels",
        "Cross-omics (X) scores are null for single-omics claims by design",
        "Rationales reference published literature but have not been independently verified"
      ],
      "next_steps": "Expert panel validation planned for v3.0.0 (Paper 1 submission)"
    }
  },
  "claims": [
    {
      "id": "sf_001",
      "claim": "Spaceflight induces a hemolytic anemia phenotype characterized by elevated carbon monoxide production and increased red blood cell destruction, persisting for at least the first weeks after return to Earth.",
      "domain": "spaceflight_biology",
      "expected_R": 0.85,
      "expected_C": 0.55,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "Trudel et al. (2022, Nature Medicine) demonstrated space anemia via CO breath analysis in 14 ISS astronauts. Replicated across multiple missions but limited to ISS 6-month durations. Single-omics (hematological/metabolic measurements). Temporal stability moderate because recovery trajectory varies by individual. The mechanism of preferential splenic hemolysis has been confirmed in subsequent analyses of Inspiration4 and other commercial crew data, strengthening reproducibility.",
      "difficulty": "easy"
    },
    {
      "id": "sf_002",
      "claim": "Microgravity exposure causes significant bone mineral density loss, particularly in weight-bearing bones, at a rate of approximately 1-2% per month in the proximal femur.",
      "domain": "spaceflight_biology",
      "expected_R": 0.95,
      "expected_C": 0.5,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "Extensively replicated across Skylab, Mir, and ISS missions (LeBlanc et al., 2000, Journal of Musculoskeletal and Neuronal Interactions; Vico et al., 2000, The Lancet). DEXA-validated measurements across dozens of crew members spanning four decades of spaceflight. Condition-specific to actual microgravity — bed rest analogs show attenuated effects. Rate varies by skeletal site with the calcaneus and femoral neck most affected. Well-established over decades of observation with consistent quantitative estimates.",
      "difficulty": "easy"
    },
    {
      "id": "sf_003",
      "claim": "Spaceflight causes a shift in the immune system toward a pro-inflammatory state, with elevated levels of circulating cytokines including IL-6 and IL-8 observed during and immediately after orbital missions.",
      "domain": "spaceflight_biology",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.65,
      "expected_X": 0.6,
      "expected_T": 0.55,
      "rationale": "Multiple studies including Crucian et al. (2015, Journal of Allergy and Clinical Immunology) and the NASA Twins Study show immune dysregulation. However, the direction of change (pro- vs anti-inflammatory) is not always consistent, and sample sizes are very small (typically n<20). Cross-omics partial: transcriptomic and proteomic data sometimes diverge on specific cytokine directionality. Temporal stability low because cytokine profiles fluctuate throughout missions and vary with mission phase.",
      "difficulty": "medium"
    },
    {
      "id": "sf_004",
      "claim": "Telomere length increases during long-duration spaceflight and shortens rapidly upon return to Earth, as demonstrated in the NASA Twins Study.",
      "domain": "spaceflight_biology",
      "expected_R": 0.5,
      "expected_C": 0.3,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.35,
      "rationale": "Garrett-Bakelman et al. (2019, Science) reported this in the Twins Study (n=1 spaceflight, n=1 ground control). Some replication in JAXA astronaut studies but inconsistent magnitude and duration of effect. Highly condition-specific — confounded by diet, stress, radiation exposure, and exercise regimen. Temporal stability poor: telomere dynamics are inherently variable and the inflight elongation is transient, with rapid shortening post-flight followed by variable recovery trajectories.",
      "difficulty": "hard"
    },
    {
      "id": "sf_005",
      "claim": "Cell-free RNA (cfRNA) profiles in astronaut blood plasma can distinguish pre-flight, in-flight, and post-flight physiological states with distinct temporal signatures.",
      "domain": "spaceflight_biology",
      "expected_R": 0.55,
      "expected_C": 0.4,
      "expected_M": 0.65,
      "expected_X": 0.5,
      "expected_T": 0.45,
      "rationale": "Emerging data from the JAXA and SpaceX Inspiration4 missions support cfRNA as a spaceflight biomarker (Overbey et al., 2024, Nature). Small sample sizes (n=4 for Inspiration4) limit reproducibility assessment. Methodologically sound RNA-seq pipelines are well-validated but spaceflight-specific confounders including stress and circadian disruption are hard to control. Cross-omics concordance with cfDNA and metabolomics is partial but promising for multi-modal biomarker panels.",
      "difficulty": "hard"
    },
    {
      "id": "sf_006",
      "claim": "Spaceflight-associated neuro-ocular syndrome (SANS) is characterized by optic disc edema, globe flattening, and choroidal folds, and is associated with cephalad fluid shifts in microgravity.",
      "domain": "spaceflight_biology",
      "expected_R": 0.9,
      "expected_C": 0.45,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Well-documented in ISS astronauts (Mader et al., 2011, Ophthalmology; Lee et al., 2020, JAMA Ophthalmology). Replicated across multiple ISS expeditions with consistent ophthalmological findings including OCT measurements. Condition-specific: occurs primarily during long-duration missions and varies by individual susceptibility, with approximately 60-70% of long-duration crew showing some SANS features. Non-omics clinical observation, so X is null. Stable finding since first description.",
      "difficulty": "easy"
    },
    {
      "id": "sf_007",
      "claim": "Galactic cosmic radiation exposure during spaceflight induces persistent DNA damage response signaling, with elevated levels of phosphorylated H2AX (gamma-H2AX) foci in peripheral blood lymphocytes.",
      "domain": "spaceflight_biology",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "Cucinotta et al. (2008, Radiation Research) and multiple radiation biology studies confirm gamma-H2AX elevation in astronaut blood samples. Ground-based HZE particle studies at NSRL corroborate the finding. Condition-specific to radiation type, dose rate, and shielding configuration. Cross-omics partially supported by transcriptomic DDR pathway activation data from GeneLab. Temporal stability moderate — foci resolve over weeks but some persistent foci indicate complex DSBs.",
      "difficulty": "medium"
    },
    {
      "id": "sf_008",
      "claim": "Spaceflight causes reactivation of latent herpes viruses (EBV, VZV, CMV) in astronauts, associated with immune system dysregulation during orbital missions.",
      "domain": "spaceflight_biology",
      "expected_R": 0.9,
      "expected_C": 0.55,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "Mehta et al. (2014, Journal of Medical Virology; 2017, Frontiers in Microbiology) demonstrated viral reactivation in multiple ISS crews via PCR-based viral shedding assays in saliva, urine, and blood. Highly replicated across ISS expeditions with consistent detection of EBV and VZV shedding. Condition-specific — not all astronauts show clinically significant reactivation, and ground-analog Antarctic winter-over studies partially replicate the immune suppression component. Single-omics virology/immunology assessments.",
      "difficulty": "easy"
    },
    {
      "id": "sf_009",
      "claim": "Transcriptomic analysis of astronaut whole blood reveals upregulation of oxidative stress response pathways (NRF2/KEAP1 signaling) during spaceflight.",
      "domain": "spaceflight_biology",
      "expected_R": 0.65,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Reported in the Twins Study (Garrett-Bakelman et al., 2019, Science) and corroborated by rodent studies aboard ISS analyzed through NASA GeneLab. Small human sample sizes limit definitive conclusions. Methodologically adequate RNA-seq but batch effects across missions and platforms are a concern. Partial cross-omics support from metabolomics showing oxidized glutathione ratios. Temporal stability moderate — pathway activation waxes and wanes during flight phases and varies with radiation exposure events.",
      "difficulty": "medium"
    },
    {
      "id": "sf_010",
      "claim": "Astronaut gut microbiome composition shifts during spaceflight, with decreased microbial diversity and altered Firmicutes-to-Bacteroidetes ratios observed in ISS crew members.",
      "domain": "spaceflight_biology",
      "expected_R": 0.55,
      "expected_C": 0.35,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.4,
      "rationale": "Voorhies et al. (2019, Scientific Reports) and Inspiration4 data show microbiome changes in spaceflight crew. However, direction and magnitude of diversity changes vary across studies, and the Firmicutes-to-Bacteroidetes ratio framework is increasingly considered oversimplistic. Diet confounders including pre-packaged ISS food are significant. 16S rRNA and shotgun metagenomics approaches are not always concordant. Cross-omics correlation with metabolomics is limited. Temporal profiles are highly variable between individuals.",
      "difficulty": "medium"
    },
    {
      "id": "sf_011",
      "claim": "Spaceflight induces cardiac remodeling including left atrial enlargement and changes in cardiac output, partially reversible upon return to 1g.",
      "domain": "spaceflight_biology",
      "expected_R": 0.75,
      "expected_C": 0.5,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Echocardiographic data from multiple ISS missions (Hughson et al., 2016, Journal of Applied Physiology; Norsk et al., 2015, Journal of Physiology) confirm cardiac structural and functional changes during microgravity exposure. Replicated across cohorts but sample sizes remain small (typically n<15 per study). Condition-specific to mission duration and individual pre-flight cardiovascular fitness level. Clinical imaging only, so X is null. Recovery trajectories vary but most changes resolve within months.",
      "difficulty": "medium"
    },
    {
      "id": "sf_012",
      "claim": "Mitochondrial dysfunction is a convergent molecular pathway across multiple tissues and organ systems affected by spaceflight, as identified by multi-omics integration of NASA GeneLab datasets.",
      "domain": "spaceflight_biology",
      "expected_R": 0.7,
      "expected_C": 0.7,
      "expected_M": 0.65,
      "expected_X": 0.75,
      "expected_T": 0.6,
      "rationale": "da Silveira et al. (2020, Cell) identified mitochondrial stress as a convergent theme from GeneLab meta-analysis across rodent and human datasets spanning liver, muscle, blood, and retinal tissues. Cross-omics concordance is a key strength — transcriptomics, proteomics, and metabolomics converge on mitochondrial pathways. However, much data derives from rodent models with limited human replication. Analytical approach (meta-analysis of heterogeneous datasets) is statistically robust but heterogeneous source data quality introduces uncertainty.",
      "difficulty": "medium"
    },
    {
      "id": "sf_013",
      "claim": "Spaceflight causes epigenetic changes including altered DNA methylation patterns at stress-response gene promoters, some of which persist for months after return to Earth.",
      "domain": "spaceflight_biology",
      "expected_R": 0.5,
      "expected_C": 0.35,
      "expected_M": 0.6,
      "expected_X": 0.5,
      "expected_T": 0.4,
      "rationale": "Twins Study reported methylation changes at thousands of CpG sites, and Inspiration4 data (Overbey et al., 2024, Nature) corroborate spaceflight-associated epigenomic shifts. However, distinguishing spaceflight-specific epigenetic changes from aging, psychological stress, and circadian disruption effects is methodologically difficult. Small n, limited independent replication. Cross-omics partial: some concordance with transcriptomics at differentially methylated promoters but not consistently. Persistence of changes beyond 6 months is debated.",
      "difficulty": "medium"
    },
    {
      "id": "sf_014",
      "claim": "Urinary calcium excretion increases during spaceflight due to accelerated bone resorption, elevating the risk of renal stone formation in astronauts.",
      "domain": "spaceflight_biology",
      "expected_R": 0.9,
      "expected_C": 0.55,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "Classical spaceflight physiology finding confirmed in Skylab, Mir, and ISS missions (Whitson et al., 1999, Journal of Urology; Smith et al., 2012, Bone). Well-replicated with direct clinical chemistry measurements across dozens of astronauts over multiple decades. Condition-specific — countermeasures including bisphosphonates and resistive exercise can attenuate calcium loss. Single clinical chemistry domain. At least one ISS crew member has experienced a symptomatic renal stone, validating the clinical relevance of the finding.",
      "difficulty": "easy"
    },
    {
      "id": "sf_015",
      "claim": "Muscle atrophy during spaceflight preferentially affects postural (type I slow-twitch) muscles, with the soleus showing greater volume loss than upper extremity muscles.",
      "domain": "spaceflight_biology",
      "expected_R": 0.9,
      "expected_C": 0.5,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.85,
      "rationale": "Extensively documented from Skylab through ISS (Fitts et al., 2010, Journal of Physiology; Trappe et al., 2009, Journal of Applied Physiology). MRI-validated muscle volume changes showing 10-20% soleus atrophy in 6-month missions. Highly replicated across crew cohorts. Condition-specific — countermeasure protocols using the Advanced Resistive Exercise Device (ARED) can mitigate losses significantly. Temporal stability high: consistent finding across decades of spaceflight research with quantitatively reproducible estimates.",
      "difficulty": "easy"
    },
    {
      "id": "sf_016",
      "claim": "Clonal hematopoiesis of indeterminate potential (CHIP) mutations may be enriched in astronauts exposed to chronic low-dose ionizing radiation during spaceflight.",
      "domain": "spaceflight_biology",
      "expected_R": 0.3,
      "expected_C": 0.3,
      "expected_M": 0.5,
      "expected_X": null,
      "expected_T": 0.25,
      "rationale": "Emerging hypothesis with very limited direct evidence in astronaut cohorts. Radiation biology ground studies using proton and heavy ion beams support biological plausibility for radiation-driven clonal expansion. Human spaceflight data are preliminary, and CHIP prevalence is strongly confounded by age (increases ~10% per decade after age 40). Cross-omics support from whole-genome sequencing and single-cell approaches is sparse. Temporal assessment is inherently difficult — CHIP accumulates over years, and long-term astronaut follow-up cohorts are small.",
      "difficulty": "hard"
    },
    {
      "id": "sf_017",
      "claim": "Spaceflight causes orthostatic intolerance upon return to Earth, with reduced baroreflex sensitivity and impaired cerebral autoregulation observed in the majority of returning long-duration crew members.",
      "domain": "spaceflight_biology",
      "expected_R": 0.85,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Well-established clinical finding documented since Mercury/Gemini era (Buckey et al., 1996, Journal of Applied Physiology; Meck et al., 2001, Journal of Applied Physiology). Tilt-table testing post-landing provides robust and standardized physiological data. Condition-specific — severity varies with mission duration, individual cardiovascular fitness, and fluid loading countermeasures applied before re-entry. Long track record of consistent observation spanning six decades of human spaceflight.",
      "difficulty": "easy"
    },
    {
      "id": "sf_018",
      "claim": "Multi-omics profiling of the SpaceX Inspiration4 crew revealed that the majority of molecular and physiological changes returned to baseline within 3 months of return to Earth.",
      "domain": "spaceflight_biology",
      "expected_R": 0.45,
      "expected_C": 0.35,
      "expected_M": 0.75,
      "expected_X": 0.7,
      "expected_T": 0.5,
      "rationale": "Overbey et al. (2024, Nature) reported multi-omics recovery in the Inspiration4 civilian crew (n=4, 3-day LEO mission). Methodologically rigorous multi-omics design integrating genomics, transcriptomics, proteomics, metabolomics, and epigenomics. However, very short mission duration (3 days) limits generalizability to long-duration spaceflight. Only one mission crew analyzed. Cross-omics concordance was a notable study strength. Temporal recovery pattern may not hold for 6-month or year-long missions.",
      "difficulty": "medium"
    },
    {
      "id": "sf_019",
      "claim": "Spaceflight activates the innate immune system while suppressing adaptive immune cell function, creating a paradoxical immune state that increases susceptibility to both infection and inflammatory conditions.",
      "domain": "spaceflight_biology",
      "expected_R": 0.6,
      "expected_C": 0.4,
      "expected_M": 0.6,
      "expected_X": 0.5,
      "expected_T": 0.45,
      "rationale": "Multiple studies support aspects of this model (Crucian et al., 2018, Journal of Leukocyte Biology; Bigley et al., 2019, NPJ Microgravity) but the 'paradoxical immune state' framing oversimplifies complex immunological data from flow cytometry, functional assays, and cytokine panels. NK cell cytotoxicity reduction and T-cell proliferative impairment are documented but variable in magnitude. Cross-omics data (flow cytometry + transcriptomics + cytokine panels) partially converge. Temporal dynamics of the immune shift vary by individual and mission phase.",
      "difficulty": "medium"
    },
    {
      "id": "sf_020",
      "claim": "Circulating cell-free mitochondrial DNA (cf-mtDNA) levels are elevated in astronaut blood samples during spaceflight and correlate with markers of oxidative stress and inflammation.",
      "domain": "spaceflight_biology",
      "expected_R": 0.45,
      "expected_C": 0.35,
      "expected_M": 0.55,
      "expected_X": 0.5,
      "expected_T": 0.4,
      "rationale": "Emerging biomarker with data from Inspiration4 and limited ISS studies. cf-mtDNA as a damage-associated molecular pattern (DAMP) is biologically plausible given the mitochondrial stress convergence identified by da Silveira et al. (2020, Cell). Small sample sizes and variable collection/processing protocols limit reproducibility estimates. Correlation with oxidative stress markers including 8-OHdG and isoprostanes provides partial cross-omics support but causality is not established. Temporal dynamics during flight are poorly characterized.",
      "difficulty": "medium"
    },
    {
      "id": "sf_021",
      "claim": "Chronic exposure to galactic cosmic rays during deep-space missions increases lifetime attributable risk of radiation-induced carcinogenesis by 5-15%, based on extrapolations from the NASA Space Cancer Risk (NSCR) model and ground-based heavy-ion experiments at the NASA Space Radiation Laboratory.",
      "domain": "spaceflight_biology",
      "expected_R": 0.6,
      "expected_C": 0.35,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "The NSCR model (Cucinotta et al., 2013, PLoS ONE) provides risk estimates but relies heavily on Japanese atomic bomb survivor data extrapolated to space radiation quality factors. Ground-based HZE experiments at NSRL (Brookhaven) show elevated tumor incidence in rodents (Barcellos-Hoff et al., 2015, Life Sciences in Space Research). However, the extrapolation from acute terrestrial radiation to chronic low-dose-rate GCR involves large uncertainties (2-5x). No direct human deep-space cancer epidemiology exists. Risk model outputs are sensitive to shielding assumptions and biological effectiveness factors.",
      "difficulty": "medium"
    },
    {
      "id": "sf_022",
      "claim": "Cephalad fluid redistribution in microgravity causes a sustained increase in intracranial pressure that is the primary mechanism driving spaceflight-associated neuro-ocular syndrome (SANS) pathogenesis.",
      "domain": "spaceflight_biology",
      "expected_R": 0.55,
      "expected_C": 0.4,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Direct intracranial pressure measurement in microgravity is extremely difficult; most evidence is indirect via MRI-based techniques and optic nerve sheath diameter measurements (Kramer et al., 2020, Radiology). Head-down tilt bed rest studies (6-degree, 60-day) partially replicate ICP elevation but with attenuated SANS features (Laurie et al., 2020, JAMA Ophthalmology). Not all astronauts develop SANS despite documented fluid shifts, suggesting ICP alone is insufficient. Competing hypotheses include lymphatic drainage impairment and venous outflow obstruction. The 'primary mechanism' claim is likely an oversimplification.",
      "difficulty": "hard"
    },
    {
      "id": "sf_023",
      "claim": "Circadian rhythm disruption aboard the ISS, driven by 16 sunrise-sunset cycles per 24 hours and artificial lighting schedules, impairs astronaut sleep quality and is associated with reduced cognitive performance on psychomotor vigilance tasks.",
      "domain": "spaceflight_biology",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "Barger et al. (2014, The Lancet Neurology) documented that ISS crew members average 5.96 hours of sleep per night with frequent use of sleep medication. Actigraphy data from multiple ISS expeditions confirm disrupted sleep-wake patterns (Flynn-Evans et al., 2016, NPJ Microgravity). Installation of tunable LED lighting on ISS (2016) aimed to mitigate circadian disruption. PVT performance deficits correlate with sleep loss. Consistent finding across missions, though the magnitude of cognitive impairment varies with individual resilience and countermeasure compliance.",
      "difficulty": "easy"
    },
    {
      "id": "sf_024",
      "claim": "Arabidopsis thaliana grown aboard the International Space Station exhibits a distinct spaceflight transcriptomic signature involving upregulation of heat shock proteins, cell wall remodeling genes, and oxidative stress response pathways compared to ground controls.",
      "domain": "spaceflight_biology",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Paul et al. (2012, BMC Genomics; 2017, BMC Genomics) demonstrated spaceflight transcriptomic responses in Arabidopsis across multiple ISS experiments (APEX, BRIC). Replicated across independent growth chambers and missions. Cell wall remodeling and oxidative stress pathways consistently appear as top differential expression categories. Condition-specific to growth hardware, lighting, and watering systems. Root growth directionality changes (skewing and waving) also documented. GeneLab hosts multiple plant spaceflight datasets supporting reproducibility.",
      "difficulty": "medium"
    },
    {
      "id": "sf_025",
      "claim": "The ISS environmental microbiome is dominated by human-associated bacterial genera including Staphylococcus, Corynebacterium, and Streptococcus, with evidence of increased antimicrobial resistance gene prevalence compared to terrestrial built environments.",
      "domain": "spaceflight_biology",
      "expected_R": 0.8,
      "expected_C": 0.45,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Singh et al. (2018, Microbiome) characterized the ISS environmental microbiome through the Microbial Tracking studies across multiple sampling campaigns. Venkateswaran et al. (2014, Microbiome) reported environmental isolates with AMR genes. Replicated across multiple ISS sampling sessions over several years. Dominance of human-associated taxa is consistent with a closed, human-occupied habitat. AMR gene prevalence claim is based on limited metagenomic data and functional validation is sparse. Environmental conditions (HEPA filtration, humidity, cleaning protocols) vary over time.",
      "difficulty": "medium"
    },
    {
      "id": "sf_026",
      "claim": "The Combined Operational Load-Bearing External Resistance Treadmill (COLBERT) and Cycle Ergometer with Vibration Isolation Stabilization (CEVIS) aboard ISS effectively maintain astronaut aerobic capacity (VO2max) within 5-10% of pre-flight values during 6-month missions when compliance with prescribed exercise protocols exceeds 80%.",
      "domain": "spaceflight_biology",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Moore et al. (2014, Medicine and Science in Sports and Exercise) reported VO2max preservation in ISS crew members using integrated countermeasure exercise programs. The combination of treadmill, cycle ergometer, and resistive exercise (ARED) appears effective. However, individual compliance and pre-flight fitness levels strongly modulate outcomes. Some crew members still show >10% VO2max decline despite exercise. Pre-ARED era showed substantially greater deconditioning. Consistent finding across ISS increments since the full countermeasure suite became available.",
      "difficulty": "easy"
    },
    {
      "id": "sf_027",
      "claim": "Pharmaceutical drug stability is compromised during spaceflight due to elevated radiation exposure and storage temperature fluctuations, with analgesics and antibiotics showing accelerated degradation compared to ground-stored controls.",
      "domain": "spaceflight_biology",
      "expected_R": 0.65,
      "expected_C": 0.4,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Du et al. (2011, AAPS Journal) analyzed ISS-stored pharmaceuticals and found accelerated potency loss in several drug classes. Wotring (2016, AAPS Journal) confirmed that medication efficacy degrades faster in the spaceflight environment, with some formulations losing >10% potency before their stated expiration date. Limited number of drug types tested. Radiation contribution versus temperature/humidity effects are difficult to disentangle. Critical for long-duration deep-space missions where resupply is impossible. Evidence base remains thin with small sample sizes of returned medications.",
      "difficulty": "medium"
    },
    {
      "id": "sf_028",
      "claim": "Wound healing is significantly impaired in microgravity, with rodent studies aboard ISS showing delayed cutaneous wound closure, reduced collagen deposition, and attenuated inflammatory cell recruitment compared to ground controls.",
      "domain": "spaceflight_biology",
      "expected_R": 0.6,
      "expected_C": 0.45,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Radek et al. (2008, Journal of Applied Physiology) showed delayed wound healing in hindlimb unloading models. Limited direct spaceflight wound healing data exists in rodents; most evidence comes from simulated microgravity (clinostat, rotating wall vessel) cell culture studies showing impaired fibroblast migration and keratinocyte proliferation (Cialdai et al., 2017, Frontiers in Physiology). Human spaceflight wound healing data is essentially anecdotal. The claim extrapolates heavily from ground analogs to actual spaceflight conditions.",
      "difficulty": "hard"
    },
    {
      "id": "sf_029",
      "claim": "Human CD34+ hematopoietic stem and progenitor cells cultured in simulated microgravity using rotating wall vessel bioreactors show enhanced self-renewal and altered differentiation bias toward the myeloid lineage compared to static 1g cultures.",
      "domain": "spaceflight_biology",
      "expected_R": 0.5,
      "expected_C": 0.4,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.45,
      "rationale": "Davis et al. (2006, Stem Cells and Development) and Low et al. (2001, Biotechnology and Bioengineering) reported altered HSPC behavior in simulated microgravity. However, rotating wall vessel conditions are an imperfect analog for true microgravity. Results vary by donor, cytokine cocktail, and culture duration. Limited ISS-based stem cell experiments have been conducted. Cross-omics support from transcriptomic profiling is sparse. Translational relevance to astronaut hematopoiesis in vivo remains speculative.",
      "difficulty": "hard"
    },
    {
      "id": "sf_030",
      "claim": "Vestibular adaptation to microgravity follows a predictable time course, with space motion sickness symptoms peaking within the first 48-72 hours and substantially resolving by mission day 7-10, accompanied by sensory reweighting from otolith to visual and proprioceptive cues.",
      "domain": "spaceflight_biology",
      "expected_R": 0.85,
      "expected_C": 0.55,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "Well-established from Space Shuttle and ISS missions (Reschke et al., 1998, Journal of Vestibular Research; Clément et al., 2020, Neuroscience and Biobehavioral Reviews). Approximately 60-80% of crew members experience space motion sickness with the described time course. Neurovestibular adaptation model is supported by posturography, ocular counter-rolling, and subjective symptom data. Individual variation in susceptibility and recovery rate is significant but the general temporal pattern is robust across missions and space agencies.",
      "difficulty": "easy"
    },
    {
      "id": "sf_031",
      "claim": "Spaceflight-associated increases in intracranial pressure, as inferred from MRI measurements of optic nerve sheath diameter and ventricular volume, persist for at least 6 months after return from 6-month ISS missions.",
      "domain": "spaceflight_biology",
      "expected_R": 0.5,
      "expected_C": 0.35,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.45,
      "rationale": "Roberts et al. (2017, New England Journal of Medicine; 2019, JAMA Neurology) showed ventricular enlargement persisting post-flight using brain MRI. However, ventricular volume is an indirect proxy for ICP. Not all crew members show persistent changes. The relationship between ventricular volume, true ICP, and clinical significance is unclear. Some structural brain changes including upward shift of the brain vertex and central sulcus narrowing have been documented but their functional consequences remain debated.",
      "difficulty": "hard"
    },
    {
      "id": "sf_032",
      "claim": "Astronaut visual acuity degrades during long-duration spaceflight, with hyperopic shifts observed in approximately 30-50% of ISS crew members, consistent with posterior globe flattening documented by orbital ultrasound and MRI.",
      "domain": "spaceflight_biology",
      "expected_R": 0.85,
      "expected_C": 0.45,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Mader et al. (2011, Ophthalmology) first reported the clinical findings in long-duration crew. Lee et al. (2020, JAMA Ophthalmology) provided prevalence data across ISS expeditions. Visual acuity changes documented by standardized on-orbit visual testing. The hyperopic shift mechanism is linked to SANS pathophysiology. Well-replicated across ISS increments with consistent rates. Not all crew members affected, suggesting individual susceptibility factors including anatomical differences in optic nerve sheath compliance and vascular anatomy.",
      "difficulty": "easy"
    },
    {
      "id": "sf_033",
      "claim": "Sleep quality in astronauts aboard the ISS is significantly impaired compared to pre-flight baselines, with wrist actigraphy showing reduced total sleep time, increased sleep fragmentation, and frequent use of sleep-promoting medications by over 75% of crew members.",
      "domain": "spaceflight_biology",
      "expected_R": 0.85,
      "expected_C": 0.5,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "Barger et al. (2014, The Lancet Neurology) conducted the largest study of astronaut sleep using actigraphy and flight surgeon reports. Sleep medication use rate is well-documented through ISS medical operations data. Replicated across multiple ISS expeditions and consistent with prior Shuttle-era findings (Dijk et al., 2001, American Journal of Physiology). Individual variation in sleep impairment is significant. Installation of tunable SSLA LED lighting in ISS modules (2016) was intended as a countermeasure but long-term efficacy data are still being collected.",
      "difficulty": "easy"
    },
    {
      "id": "sf_034",
      "claim": "Cardiovascular deconditioning during spaceflight includes reduced left ventricular mass, decreased stroke volume, and plasma volume contraction of approximately 10-15%, contributing to post-flight exercise intolerance.",
      "domain": "spaceflight_biology",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Norsk et al. (2015, Journal of Physiology) documented cardiac output changes during ISS missions using rebreathing techniques. Plasma volume contraction is well-documented from Skylab era onward (Leach et al., 1996, Aviation Space and Environmental Medicine). Integrated cardiovascular deconditioning model is well-supported. Exercise countermeasures (COLBERT, CEVIS, ARED) partially mitigate but do not eliminate deconditioning. Post-flight exercise testing consistently shows reduced aerobic capacity. Quantitative estimates are consistent across space agencies and missions.",
      "difficulty": "easy"
    },
    {
      "id": "sf_035",
      "claim": "Spaceflight induces changes in hepatic enzyme activity and liver function biomarkers, with elevated serum alkaline phosphatase and altered drug metabolism capacity observed in returning ISS crew members.",
      "domain": "spaceflight_biology",
      "expected_R": 0.45,
      "expected_C": 0.35,
      "expected_M": 0.5,
      "expected_X": null,
      "expected_T": 0.4,
      "rationale": "Limited clinical chemistry data from ISS medical monitoring shows occasional liver enzyme elevations (Pietrzyk et al., 2013, Aviation Space and Environmental Medicine). Rodent studies aboard ISS show hepatic transcriptomic changes including altered cytochrome P450 expression (Jonscher et al., 2016, PLoS ONE). However, human data are sparse and confounded by dietary changes, medication use, and stress. Direct measurement of drug metabolism capacity in astronauts is essentially absent. The claim extrapolates heavily from rodent data and limited clinical biomarkers.",
      "difficulty": "hard"
    },
    {
      "id": "sf_036",
      "claim": "NASA's advanced food technology program has demonstrated that spaceflight food systems maintain adequate nutritional quality for missions up to 5 years when stored at ambient ISS cabin temperature, with no significant degradation of vitamins or macronutrient bioavailability.",
      "domain": "spaceflight_biology",
      "expected_R": 0.2,
      "expected_C": 0.2,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.25,
      "rationale": "This is a negative control claim. Cooper et al. (2011, Journal of Food Science) showed significant vitamin degradation in spaceflight food after 3 years of storage, particularly vitamins C, B1, and K. The claim of 'no significant degradation' for 5-year storage is demonstrably false. Zwart et al. (2009, American Journal of Clinical Nutrition) documented nutritional inadequacies in ISS crew diets. Extended-duration food preservation remains an unsolved challenge for Mars missions. Radiation exposure further accelerates nutrient degradation in stored food.",
      "difficulty": "easy"
    },
    {
      "id": "sf_037",
      "claim": "Cognitive performance testing using the Cognition battery (formerly WinSCAL) shows that astronaut executive function and spatial working memory remain completely unimpaired throughout 6-month ISS missions, demonstrating robust human cognitive resilience to the spaceflight environment.",
      "domain": "spaceflight_biology",
      "expected_R": 0.25,
      "expected_C": 0.2,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.3,
      "rationale": "Negative control claim. Strangman et al. (2014, Acta Astronautica) reported subtle cognitive performance decrements during ISS missions. Garrett-Bakelman et al. (2019, Science) noted cognitive speed reductions in the Twins Study. While frank cognitive impairment is not typical, 'completely unimpaired' is an overstatement. Some studies show practice effects masking genuine decline. Sleep deprivation, circadian disruption, and CO2 levels on ISS all negatively impact cognition. The absolutist 'completely unimpaired' framing is inconsistent with published data.",
      "difficulty": "easy"
    },
    {
      "id": "sf_038",
      "claim": "Fine and gross motor control is disrupted during the first days of microgravity exposure, with measurable degradation in hand-eye coordination, grip force modulation, and object manipulation that improves with adaptation over the first 2-4 weeks of a mission.",
      "domain": "spaceflight_biology",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Clément et al. (2020, Neuroscience and Biobehavioral Reviews) reviewed sensorimotor adaptation in spaceflight. Grip force modulation studies aboard ISS (Augurelle et al., 2003, Journal of Neurophysiology) document altered force control in microgravity. Pointing accuracy and hand trajectory studies show initial impairment with progressive adaptation. Well-replicated across ISS experiments. The 2-4 week adaptation timeline is consistent across studies though individual variation exists. Post-flight motor readaptation to gravity is also well-documented.",
      "difficulty": "medium"
    },
    {
      "id": "sf_039",
      "claim": "Spaceflight activates the NLRP3 inflammasome pathway in astronaut peripheral blood mononuclear cells, contributing to the sterile inflammatory state observed during orbital missions through increased IL-1beta and IL-18 secretion.",
      "domain": "spaceflight_biology",
      "expected_R": 0.4,
      "expected_C": 0.35,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.35,
      "rationale": "Emerging hypothesis supported by simulated microgravity cell culture studies showing NLRP3 activation (Thiel et al., 2017, Scientific Reports). Limited direct astronaut PBMC data exists for NLRP3 pathway components. The connection between spaceflight stressors (radiation, microgravity, psychological stress) and inflammasome activation is biologically plausible but not definitively demonstrated in human spaceflight samples. IL-1beta elevations reported in some astronaut cytokine panels provide indirect support. Cross-omics confirmation from matched transcriptomic and proteomic data is sparse.",
      "difficulty": "hard"
    },
    {
      "id": "sf_040",
      "claim": "Cosmic ray-induced carcinogenesis risk in astronauts can be fully mitigated by polyethylene shielding of 20 g/cm2 thickness surrounding habitable spacecraft volumes, reducing effective dose to below terrestrial background radiation levels.",
      "domain": "spaceflight_biology",
      "expected_R": 0.1,
      "expected_C": 0.1,
      "expected_M": 0.25,
      "expected_X": null,
      "expected_T": 0.15,
      "rationale": "Negative control claim. Polyethylene shielding is effective against solar particle events but GCR shielding is fundamentally limited by secondary particle production (nuclear fragmentation). Thick shielding can paradoxically increase dose from high-Z GCR secondaries (Slaba et al., 2015, Life Sciences in Space Research). The claim of reducing below terrestrial background is physically implausible for practical spacecraft masses. NASA radiation protection standards acknowledge that current technology cannot fully shield against GCR during interplanetary transit.",
      "difficulty": "easy"
    },
    {
      "id": "sf_041",
      "claim": "Axiom Space Mission 1 (Ax-1) crew members showed molecular and physiological responses qualitatively similar to those observed in professional NASA astronauts during ISS expeditions, suggesting that spaceflight adaptation is largely independent of pre-flight training duration and physical conditioning programs.",
      "domain": "spaceflight_biology",
      "expected_R": 0.4,
      "expected_C": 0.3,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.35,
      "rationale": "Axiom-1 data (2022) showed some overlapping molecular signatures with longer ISS missions per preliminary analyses. However, the very short mission duration (17 days) and small crew (n=4) severely limit comparisons. The claim that adaptation is 'largely independent' of training overstates the evidence — Ax-1 crew had abbreviated but still significant pre-flight preparation. Professional astronaut conditioning programs target specific countermeasures. Systematic comparison between commercial and professional crew molecular responses is ongoing but conclusions are premature.",
      "difficulty": "hard"
    },
    {
      "id": "sf_042",
      "claim": "JAXA astronaut studies conducted aboard the ISS Kibo module demonstrate that Japanese crew members exhibit a spaceflight-induced increase in urinary 8-OHdG oxidative DNA damage marker levels that correlates with cumulative radiation dose, returning to baseline within 3 months post-flight.",
      "domain": "spaceflight_biology",
      "expected_R": 0.6,
      "expected_C": 0.45,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "JAXA has conducted longitudinal biomarker studies on ISS crew (Murata et al., 2022, NPJ Microgravity). 8-OHdG as an oxidative stress biomarker is well-validated in terrestrial medicine. The correlation with cumulative radiation dose has been examined in a small JAXA astronaut cohort (n<10). Confounders including exercise, diet, and stress affect 8-OHdG levels. Recovery kinetics within 3 months are reported but inter-individual variability is substantial. Cross-omics partial: some correlation with transcriptomic oxidative stress pathways.",
      "difficulty": "medium"
    },
    {
      "id": "sf_043",
      "claim": "SpaceX Dragon spacecraft cabin atmosphere during Inspiration4 and subsequent commercial missions maintains CO2 partial pressures below the ISS operational limit of 5.3 mmHg, with no evidence of CO2-related cognitive impairment during the 3-day orbital mission.",
      "domain": "spaceflight_biology",
      "expected_R": 0.55,
      "expected_C": 0.4,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.45,
      "rationale": "Inspiration4 environmental monitoring data are limited in published literature. ISS CO2 levels have historically exceeded recommended limits (Law et al., 2014, Aviation Space and Environmental Medicine), and the smaller Dragon cabin volume presents unique atmospheric management challenges. The claim about Dragon CO2 levels is based on limited publicly available data. Cognitive testing during Inspiration4 was reported in supplementary analyses by Overbey et al. (2024, Nature) but with very small n and short mission duration. Generalizability to longer commercial missions is unknown.",
      "difficulty": "medium"
    },
    {
      "id": "sf_044",
      "claim": "Renal function biomarkers including serum creatinine, cystatin C, and estimated glomerular filtration rate show transient but consistent changes during spaceflight, with GFR increasing during the first week in microgravity due to plasma volume contraction and returning toward baseline during longer missions.",
      "domain": "spaceflight_biology",
      "expected_R": 0.55,
      "expected_C": 0.4,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Leach et al. (1996, Aviation Space and Environmental Medicine) documented early spaceflight renal hemodynamic changes. More recent ISS medical monitoring data (Pietrzyk et al., 2013, Aviation Space and Environmental Medicine) provide additional clinical chemistry data. The biphasic pattern (early increase then normalization) is physiologically consistent with fluid redistribution models. However, systematic studies with modern renal biomarkers (cystatin C, KIM-1, NGAL) in spaceflight are limited. Confounders include hydration status, dietary sodium intake, and exercise protocols.",
      "difficulty": "medium"
    },
    {
      "id": "sf_045",
      "claim": "Spaceflight completely eliminates the normal diurnal cortisol rhythm in astronauts, with flat cortisol profiles persisting throughout orbital missions and for at least 30 days after return to Earth.",
      "domain": "spaceflight_biology",
      "expected_R": 0.2,
      "expected_C": 0.15,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.2,
      "rationale": "Negative control claim. While spaceflight disrupts circadian rhythms and can alter cortisol patterns (Stuster et al., 2010, NASA Technical Report), the claim of 'complete elimination' of diurnal cortisol rhythm is an overstatement. Most studies show attenuated but preserved cortisol rhythmicity during spaceflight (Czeisler et al., NASA Neurolab data). Salivary cortisol studies on ISS crew show shifted peaks and reduced amplitude rather than flat profiles. The 30-day post-flight persistence claim lacks supporting evidence; most hormonal profiles normalize within days to weeks.",
      "difficulty": "easy"
    },
    {
      "id": "sf_046",
      "claim": "Resistive exercise using the Advanced Resistive Exercise Device (ARED) aboard ISS, combined with bisphosphonate administration, fully prevents bone mineral density loss in weight-bearing bones during 6-month missions, achieving zero net bone loss in all compliant crew members.",
      "domain": "spaceflight_biology",
      "expected_R": 0.25,
      "expected_C": 0.2,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.3,
      "rationale": "Negative control claim. While ARED plus bisphosphonates significantly reduces bone loss (LeBlanc et al., 2013, Journal of Bone and Mineral Research; Smith et al., 2012, Bone), the claim of 'fully prevents' and 'zero net bone loss in all' is an overstatement. Some skeletal sites (calcaneus, femoral neck cortical bone) continue to show modest losses even with optimal countermeasures. Individual response variability means not all crew members achieve complete protection. The absolutist framing should be flagged by any calibrated scoring system.",
      "difficulty": "easy"
    },
    {
      "id": "sf_047",
      "claim": "Simulated microgravity using clinostat rotation alters mesenchymal stem cell differentiation, favoring adipogenic over osteogenic lineage commitment through mechanosensitive signaling pathways involving YAP/TAZ nuclear translocation.",
      "domain": "spaceflight_biology",
      "expected_R": 0.55,
      "expected_C": 0.4,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Chen et al. (2016, Stem Cells and Development) and Zayzafoon et al. (2004, Journal of Cellular Biochemistry) demonstrated adipogenic bias in simulated microgravity. YAP/TAZ mechanotransduction pathway involvement is supported by Dupont et al. (2011, Nature) in general mechanobiology, with spaceflight-specific data emerging. Clinostat studies have reproducibility concerns due to residual gravity vectors and rotation speed artifacts. Actual spaceflight MSC experiments are extremely limited. Cross-omics from transcriptomics and protein localization studies partially confirm mechanism.",
      "difficulty": "medium"
    },
    {
      "id": "sf_048",
      "claim": "Astronaut venous blood samples collected during ISS expeditions show increased frequency of chromosomal aberrations including translocations and dicentrics detected by fluorescence in situ hybridization (FISH), with aberration frequency correlating with mission duration and cumulative effective dose.",
      "domain": "spaceflight_biology",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "George et al. (2001, Radiation Research; 2013, Radiation Research) conducted systematic chromosomal aberration analysis using FISH in ISS crew blood samples. Translocation frequency increases with mission duration in a dose-dependent manner. Replicated across multiple crew cohorts by the NASA Johnson Space Center cytogenetics laboratory. Individual variation in radiosensitivity affects aberration yield. FISH-based detection is well-validated but limited to detectable rearrangements; subchromosomal damage is missed. Pre-flight baseline measurements provide within-subject controls.",
      "difficulty": "medium"
    },
    {
      "id": "sf_049",
      "claim": "The spaceflight environment induces a unique transcriptomic signature in human endothelial cells that is distinct from any ground-based analog, with over 500 genes showing spaceflight-specific differential expression not recapitulated by simulated microgravity, radiation, or combined stressor treatments.",
      "domain": "spaceflight_biology",
      "expected_R": 0.35,
      "expected_C": 0.3,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.3,
      "rationale": "Versari et al. (2013, FASEB Journal) reported endothelial cell transcriptomic responses to spaceflight. However, the claim of 500+ spaceflight-specific genes not recapitulated by any analog is difficult to verify given the limited number of direct spaceflight-to-analog comparison studies. Batch effects between flight and ground experiments can inflate apparent differences. Sample sizes are extremely small. The 'unique signature' framing may reflect technical confounders rather than genuine biological uniqueness. Cross-omics validation is minimal for these claims.",
      "difficulty": "hard"
    },
    {
      "id": "sf_050",
      "claim": "Long-duration spaceflight causes persistent structural brain changes visible on MRI, including expansion of cerebral ventricles, narrowing of central sulcus, and upward displacement of brain vertex, with some changes remaining detectable one year after return to Earth.",
      "domain": "spaceflight_biology",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "Roberts et al. (2017, New England Journal of Medicine) first reported brain structural changes in astronauts using pre- and post-flight MRI. Van Ombergen et al. (2019, Science Advances) confirmed ventricular expansion and gray matter redistribution. Jillings et al. (2020, Science Advances) demonstrated persistent changes at 7 months post-flight. Replicated across independent research groups using standardized MRI protocols. Functional significance of structural changes remains debated. Not all crew members show the same pattern or magnitude of changes. Recovery trajectory varies by specific structural parameter.",
      "difficulty": "medium"
    },
    {
      "id": "cg_001",
      "claim": "TP53 is the most frequently mutated gene across human cancers, with somatic mutations detected in approximately 50% of all tumors analyzed in TCGA and PCAWG pan-cancer cohorts, serving as a key driver of genomic instability and clonal evolution.",
      "domain": "cancer_genomics",
      "expected_R": 0.95,
      "expected_C": 0.75,
      "expected_M": 0.9,
      "expected_X": null,
      "expected_T": 0.9,
      "rationale": "TCGA Pan-Cancer Atlas (Hoadley et al., 2018, Cell) and PCAWG Consortium (2020, Nature) both identify TP53 as the most commonly mutated gene across cancer types. The ~50% frequency is robust across independent cohorts and sequencing platforms. Cross-omics concordance is strong: TP53 mutations correlate with copy number instability, gene expression signatures, and protein-level loss of function. Some cancer types (ovarian serous: >95%) show near-universal TP53 mutation while others (renal clear cell: <5%) are rare. One of the most temporally stable findings in cancer genomics spanning four decades.",
      "difficulty": "easy"
    },
    {
      "id": "cg_002",
      "claim": "KRAS G12C mutations, present in approximately 13% of non-small cell lung cancers, can be therapeutically targeted by covalent inhibitors such as sotorasib and adagrasib, achieving objective response rates of 30-40% in previously treated patients.",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.45,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "CodeBreaK 100 trial for sotorasib (Skoulidis et al., 2021, New England Journal of Medicine) and KRYSTAL-1 trial for adagrasib (Janne et al., 2022, New England Journal of Medicine) demonstrated clinical activity against KRAS G12C mutant NSCLC. Response rates are reproducible across trials. However, acquired resistance develops rapidly (median PFS 6-7 months) through diverse mechanisms including KRAS mutations at other codons, bypass signaling, and epithelial-mesenchymal transition. KRAS G12C frequency varies by ethnicity and histologic subtype. Single-pathway targeted therapy assessment.",
      "difficulty": "easy"
    },
    {
      "id": "cg_003",
      "claim": "BRAF V600E mutations drive constitutive activation of the MAPK signaling pathway in melanoma, colorectal cancer, and thyroid cancer, with combination BRAF/MEK inhibitor therapy (dabrafenib plus trametinib) achieving durable responses in BRAF-mutant melanoma with median progression-free survival exceeding 12 months.",
      "domain": "cancer_genomics",
      "expected_R": 0.9,
      "expected_C": 0.45,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "COMBI-d and COMBI-v trials (Long et al., 2015, The Lancet; Robert et al., 2015, New England Journal of Medicine) established dabrafenib/trametinib combination as standard of care for BRAF V600E melanoma. Response rates >60% and median PFS of 11-14 months are well-replicated. However, context-dependent: BRAF V600E inhibition in colorectal cancer is less effective without concurrent EGFR blockade (Kopetz et al., 2019, New England Journal of Medicine). Resistance inevitably develops through MAPK reactivation, RAS mutations, or bypass pathway activation.",
      "difficulty": "easy"
    },
    {
      "id": "cg_004",
      "claim": "PIK3CA hotspot mutations (E545K, H1047R) activate the PI3K/AKT/mTOR signaling axis in approximately 30-40% of hormone receptor-positive breast cancers and can be therapeutically targeted by the alpha-selective PI3K inhibitor alpelisib in combination with fulvestrant.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.4,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "SOLAR-1 trial (Andre et al., 2019, New England Journal of Medicine) demonstrated alpelisib benefit in PIK3CA-mutant HR+/HER2- breast cancer. PIK3CA mutation frequency is well-characterized in TCGA breast cancer cohort. Clinical benefit is condition-specific: limited to HR+ subtype with confirmed PIK3CA mutation. Metabolic toxicity (hyperglycemia) limits tolerability. Acquired resistance through PTEN loss, AKT amplification, and ESR1 mutations is well-documented. Companion diagnostic (therascreen PIK3CA RGQ PCR Kit) is FDA-approved.",
      "difficulty": "medium"
    },
    {
      "id": "cg_005",
      "claim": "The tumor microenvironment (TME) in solid cancers contains functionally diverse immune cell populations whose composition, spatial organization, and activation state are stronger predictors of clinical outcome than tumor mutational burden alone, as demonstrated by multiplex immunohistochemistry and spatial transcriptomics studies.",
      "domain": "cancer_genomics",
      "expected_R": 0.75,
      "expected_C": 0.5,
      "expected_M": 0.7,
      "expected_X": 0.65,
      "expected_T": 0.6,
      "rationale": "Immunoscore (Galon et al., 2006, Science; Pages et al., 2018, The Lancet) demonstrated prognostic value of immune cell spatial distribution in colorectal cancer. Spatial transcriptomics studies (Barkley et al., 2022, Nature Genetics) confirm TME heterogeneity impacts outcomes. The claim that TME composition is 'stronger' than TMB is context-dependent — in some tumor types TMB remains a strong predictor. Cross-omics concordance from single-cell RNA-seq, multiplex IHC, and spatial transcriptomics is strong. Rapidly evolving field with methodology still maturing.",
      "difficulty": "medium"
    },
    {
      "id": "cg_006",
      "claim": "PD-1/PD-L1 immune checkpoint blockade with pembrolizumab or nivolumab produces durable clinical responses in approximately 20-40% of patients with advanced non-small cell lung cancer, with PD-L1 tumor proportion score serving as an imperfect but FDA-approved predictive biomarker.",
      "domain": "cancer_genomics",
      "expected_R": 0.9,
      "expected_C": 0.45,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "KEYNOTE-024 (Reck et al., 2016, New England Journal of Medicine), CheckMate-017/057 (Borghaei et al., 2015, New England Journal of Medicine) established ICI efficacy in NSCLC. Response rates are well-replicated across Phase III trials. PD-L1 TPS is an imperfect biomarker — some PD-L1-negative patients respond and some PD-L1-high patients do not. TMB, TIL density, and interferon-gamma gene signatures add predictive value. Long-term survival data (5-year follow-up) confirm durable responses in a subset. Context-specific: different tumor types show different response rates.",
      "difficulty": "easy"
    },
    {
      "id": "cg_007",
      "claim": "Circulating tumor DNA (ctDNA) detected in plasma cell-free DNA can serve as a real-time liquid biopsy for monitoring tumor burden, detecting minimal residual disease, and identifying acquired resistance mutations, with sensitivity improving as sequencing depth and bioinformatic methods advance.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.45,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Dawson et al. (2013, New England Journal of Medicine) demonstrated ctDNA for treatment monitoring in breast cancer. TRACERx study (Abbosh et al., 2017, Nature) showed ctDNA detection of NSCLC relapse months before radiographic progression. CAPP-seq (Newman et al., 2014, Nature Medicine) and other technologies show increasing sensitivity. Condition-specific: ctDNA shedding varies by tumor type, stage, and volume. Cross-omics integration with ctDNA methylation and fragmentomics improves accuracy. Technical standardization across laboratories remains a challenge.",
      "difficulty": "medium"
    },
    {
      "id": "cg_008",
      "claim": "Intratumor heterogeneity, driven by branched clonal evolution and genomic instability, is a fundamental feature of solid cancers that limits the efficacy of single-agent targeted therapy and contributes to acquired drug resistance through selection of pre-existing resistant subclones.",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.55,
      "expected_M": 0.8,
      "expected_X": 0.65,
      "expected_T": 0.75,
      "rationale": "TRACERx consortium (Jamal-Hanjani et al., 2017, New England Journal of Medicine) demonstrated extensive intratumor heterogeneity in NSCLC through multi-region whole-exome sequencing. Gerlinger et al. (2012, New England Journal of Medicine) established the concept of branched evolution in renal cell carcinoma. Pre-existing resistant subclones documented in melanoma (Shi et al., 2014, Nature Communications). Cross-omics from genomic, epigenomic, and single-cell data converge on heterogeneity as a universal cancer property. One of the most robust findings in cancer genomics.",
      "difficulty": "easy"
    },
    {
      "id": "cg_009",
      "claim": "Clonal evolution in acute myeloid leukemia follows a linear progression model from founding clone through successive acquisition of cooperating mutations in a predictable order: first an initiating mutation in epigenetic regulators (DNMT3A, TET2, IDH1/2), followed by signaling mutations (FLT3, NRAS), and finally proliferation-driving events.",
      "domain": "cancer_genomics",
      "expected_R": 0.55,
      "expected_C": 0.4,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Welch et al. (2012, Cell) and Papaemmanuil et al. (2016, New England Journal of Medicine) provided detailed clonal architecture of AML. The general pattern of epigenetic mutations preceding signaling mutations is supported but the claim of 'predictable order' and 'linear progression' oversimplifies the data. Many AML cases show branched evolution and variable mutation ordering. CHIP-to-AML progression (Abelson et al., 2018, Nature) supports early epigenetic mutations but subsequent evolution is stochastic. Cross-omics from paired diagnosis-relapse samples reveals complex evolutionary trajectories.",
      "difficulty": "hard"
    },
    {
      "id": "cg_010",
      "claim": "Epigenetic reprogramming through aberrant DNA methylation is a universal hallmark of cancer, with global hypomethylation of repetitive elements and focal hypermethylation of CpG island promoters leading to silencing of tumor suppressor genes including CDKN2A, MLH1, and BRCA1.",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.7,
      "expected_M": 0.8,
      "expected_X": 0.65,
      "expected_T": 0.85,
      "rationale": "Baylin and Jones (2011, Nature Reviews Cancer) comprehensively reviewed DNA methylation in cancer. TCGA pan-cancer methylation studies (Cancer Genome Atlas Research Network, multiple publications 2012-2018) confirm global hypomethylation and focal hypermethylation patterns. Specific examples: MLH1 promoter methylation in microsatellite-unstable colorectal cancer, MGMT methylation in glioblastoma. Cross-omics from methylation arrays, bisulfite sequencing, and gene expression data strongly converge. The 'universal' claim is slightly overstated as some tumors show non-canonical methylation patterns. Stable finding over two decades.",
      "difficulty": "medium"
    },
    {
      "id": "cg_011",
      "claim": "The Warburg effect in cancer cells — preferential aerobic glycolysis over oxidative phosphorylation — is now understood to be complemented by mitochondrial metabolism and glutamine anaplerosis, with metabolic plasticity allowing tumor cells to switch between glycolytic and oxidative states depending on microenvironmental conditions.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.7,
      "expected_M": 0.75,
      "expected_X": 0.6,
      "expected_T": 0.7,
      "rationale": "DeBerardinis et al. (2008, Cell Metabolism) and Hensley et al. (2016, Cell) demonstrated that many tumors maintain active oxidative phosphorylation alongside glycolysis. In vivo isotope tracing studies (Faubert et al., 2017, Cell) confirmed metabolic heterogeneity in human NSCLC. Glutamine dependency first described by Wise et al. (2008, Proceedings of the National Academy of Sciences). Cross-omics from metabolomics, transcriptomics, and flux analysis converge. The binary Warburg/OXPHOS dichotomy is now considered oversimplistic. Metabolic plasticity under therapy selection is well-documented.",
      "difficulty": "medium"
    },
    {
      "id": "cg_012",
      "claim": "PARP inhibitors (olaparib, rucaparib, niraparib) exploit synthetic lethality in BRCA1/2-mutant cancers by preventing single-strand break repair in cells already deficient in homologous recombination, achieving progression-free survival benefits of 10-20 months in ovarian cancer maintenance therapy.",
      "domain": "cancer_genomics",
      "expected_R": 0.9,
      "expected_C": 0.45,
      "expected_M": 0.9,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "SOLO-1 trial (Moore et al., 2018, New England Journal of Medicine) showed dramatic PFS benefit for olaparib maintenance in BRCA-mutant ovarian cancer. NOVA trial (Mirza et al., 2016, New England Journal of Medicine) confirmed niraparib activity. PARP inhibitor synthetic lethality is one of the most successful translational cancer genomics stories. Condition-specific: benefit extends beyond BRCA to HRD-positive tumors but magnitude varies. Acquired resistance through BRCA reversion mutations (Quigley et al., 2017, Cancer Discovery), 53BP1 loss, and drug efflux occurs. Clinical development is mature with multiple FDA-approved indications.",
      "difficulty": "easy"
    },
    {
      "id": "cg_013",
      "claim": "Chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 achieves complete remission rates of 70-90% in relapsed/refractory B-cell acute lymphoblastic leukemia, though durability is limited by antigen loss, T-cell exhaustion, and the hostile tumor microenvironment in solid tumors.",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.4,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "Maude et al. (2018, New England Journal of Medicine) reported 83% complete remission with tisagenlecleucel in pediatric/young adult B-ALL. ZUMA-1 trial (Neelapu et al., 2017, New England Journal of Medicine) showed CD19 CAR-T efficacy in diffuse large B-cell lymphoma. CR rates are well-replicated across multiple centers and products. However, durability is limited — 30-50% relapse within 1 year, often with CD19-negative escape. Solid tumor efficacy remains a major unsolved challenge due to TME immunosuppression, antigen heterogeneity, and T-cell trafficking. Cytokine release syndrome and neurotoxicity are significant toxicities.",
      "difficulty": "medium"
    },
    {
      "id": "cg_014",
      "claim": "The Cancer Genome Atlas (TCGA) pan-cancer analysis of over 10,000 tumors across 33 cancer types identified recurrent driver mutations, copy number alterations, and gene fusions that converge on approximately 10 canonical signaling pathways, suggesting a finite and therapeutically targetable set of oncogenic mechanisms.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.55,
      "expected_M": 0.85,
      "expected_X": 0.7,
      "expected_T": 0.75,
      "rationale": "Sanchez-Vega et al. (2018, Cell) analyzed oncogenic signaling pathways across TCGA. The 10-pathway convergence model is a useful framework. Replicated by PCAWG (2020, Nature) with whole-genome sequencing identifying additional non-coding drivers. Cross-omics concordance from DNA, RNA, and protein data is a strength of TCGA. However, the '10 pathway' framework oversimplifies extensive inter-pathway crosstalk, tumor-type-specific biology, and non-cell-autonomous drivers. The implication that these are all 'therapeutically targetable' remains aspirational for many pathways.",
      "difficulty": "medium"
    },
    {
      "id": "cg_015",
      "claim": "Tumor mutational burden (TMB) measured by whole-exome sequencing or targeted gene panels is an FDA-approved pan-cancer biomarker for immune checkpoint inhibitor response, with TMB-High tumors (>=10 mutations/Mb) showing improved response rates to pembrolizumab regardless of cancer type.",
      "domain": "cancer_genomics",
      "expected_R": 0.65,
      "expected_C": 0.4,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "KEYNOTE-158 (Marabelle et al., 2020, The Lancet Oncology) supported FDA approval of pembrolizumab for TMB-High solid tumors. However, the 10 mut/Mb threshold is controversial — McGrail et al. (2021, Annals of Oncology) showed that TMB predictive value is cancer-type dependent. Panel-based TMB estimation introduces platform-dependent variability. TMB-High enriches for response but many TMB-High patients do not respond and some TMB-Low patients do. Integration with PD-L1, MSI status, and immune gene signatures improves prediction. The pan-cancer biomarker framing is debated.",
      "difficulty": "medium"
    },
    {
      "id": "cg_016",
      "claim": "Microsatellite instability-high (MSI-H) tumors arising from defective DNA mismatch repair (dMMR) exhibit high neoantigen burden and robust immune infiltration, making them among the most responsive cancer subtypes to PD-1 blockade across tissue types, as demonstrated by the KEYNOTE-177 and CheckMate-142 trials.",
      "domain": "cancer_genomics",
      "expected_R": 0.9,
      "expected_C": 0.5,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "Le et al. (2015, New England Journal of Medicine; 2017, Science) established MSI-H/dMMR as a tissue-agnostic biomarker for PD-1 blockade, leading to the first tissue-agnostic FDA approval (pembrolizumab for MSI-H/dMMR). KEYNOTE-177 (Andre et al., 2020, New England Journal of Medicine) confirmed first-line benefit in MSI-H colorectal cancer. The biological rationale (high TMB leading to neoantigens driving immune response) is well-supported by cross-omics data. Not all MSI-H patients respond (response rate ~40-50%), and MSI-H detection methods require standardization.",
      "difficulty": "medium"
    },
    {
      "id": "cg_017",
      "claim": "The BCR-ABL1 fusion gene resulting from the Philadelphia chromosome translocation t(9;22) in chronic myeloid leukemia is the paradigmatic example of targeted therapy in oncology, with imatinib achieving 10-year overall survival rates exceeding 80% and establishing the template for precision oncology.",
      "domain": "cancer_genomics",
      "expected_R": 0.95,
      "expected_C": 0.5,
      "expected_M": 0.9,
      "expected_X": null,
      "expected_T": 0.9,
      "rationale": "Druker et al. (2001, New England Journal of Medicine) established imatinib as a transformative therapy for CML. IRIS trial long-term follow-up confirmed >80% 10-year OS (Hochhaus et al., 2017, New England Journal of Medicine). The most replicated targeted therapy outcome in oncology history. Resistance through BCR-ABL kinase domain mutations (T315I) led to development of second and third-generation TKIs (dasatinib, nilotinib, ponatinib). Treatment-free remission is achievable in a subset of patients with deep molecular response. A cornerstone of precision oncology.",
      "difficulty": "easy"
    },
    {
      "id": "cg_018",
      "claim": "ALK-EML4 gene fusions define a clinically actionable molecular subtype of non-small cell lung cancer (approximately 3-5% of NSCLC), with sequential ALK tyrosine kinase inhibitors (crizotinib, alectinib, lorlatinib) achieving cumulative median overall survival exceeding 5 years in ALK-positive patients.",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.45,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Soda et al. (2007, Nature) identified EML4-ALK fusion in NSCLC. ALEX trial (Peters et al., 2017, New England Journal of Medicine) established alectinib as first-line therapy. CROWN trial (Shaw et al., 2020, New England Journal of Medicine) showed lorlatinib superiority. Sequential TKI use in ALK+ NSCLC has dramatically improved survival. Resistance mutations in the ALK kinase domain (G1202R, compound mutations) drive sequential therapy. FISH, IHC, and NGS-based detection methods are well-standardized. A success story of genomics-driven oncology.",
      "difficulty": "easy"
    },
    {
      "id": "cg_019",
      "claim": "Chromothripsis, a catastrophic genomic rearrangement event involving the shattering and random reassembly of one or a few chromosomes, occurs in approximately 20-40% of cancers and can generate oncogenic fusions and amplifications in a single cell division cycle.",
      "domain": "cancer_genomics",
      "expected_R": 0.75,
      "expected_C": 0.5,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Stephens et al. (2011, Cell) first described chromothripsis. PCAWG consortium (Cortés-Ciriano et al., 2020, Nature Genetics) reported chromothripsis in ~20-40% of cancers with variation by tumor type. Mechanism linked to micronuclei formation and bridge-fusion-breakage cycles (Zhang et al., 2015, Nature Genetics). Detection depends on whole-genome sequencing depth and bioinformatic algorithms. Cross-omics: structural variants correlate with copy number profiles and gene expression changes. Prevalence estimates vary with detection criteria. Clinical implications for therapy selection are being explored.",
      "difficulty": "medium"
    },
    {
      "id": "cg_020",
      "claim": "Disseminated tumor cells (DTCs) can establish dormant micrometastatic reservoirs in bone marrow and other distant organs years before clinically detectable metastasis, with single-cell genomic profiling revealing that early-disseminated cells harbor fewer mutations than the primary tumor, suggesting dissemination occurs early in tumor evolution.",
      "domain": "cancer_genomics",
      "expected_R": 0.65,
      "expected_C": 0.4,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Harper et al. (2016, Nature) demonstrated early dissemination in breast cancer mouse models with genomic characterization of DTCs. Hosseini et al. (2016, Nature) showed early-disseminated cells have fewer mutations. Braun et al. (2005, New England Journal of Medicine) documented bone marrow DTC detection as prognostic. Human validation is limited by the difficulty of sampling bone marrow DTCs. Cross-omics from single-cell sequencing and lineage tracing partially support the model. The dormancy mechanisms (quiescence programs, immune evasion) are incompletely understood.",
      "difficulty": "hard"
    },
    {
      "id": "cg_021",
      "claim": "Cell-free DNA fragmentomics analysis, examining fragment size distribution, end motif patterns, and nucleosome positioning from plasma cfDNA, can detect and classify multiple cancer types with higher sensitivity than mutation-based ctDNA approaches, particularly for early-stage cancers.",
      "domain": "cancer_genomics",
      "expected_R": 0.6,
      "expected_C": 0.4,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Cristiano et al. (2019, Nature) demonstrated cfDNA fragmentome-based cancer detection (DELFI approach). Mathios et al. (2021, Nature Communications) applied fragmentomics to lung cancer detection. The claim that fragmentomics has 'higher sensitivity' than mutation-based approaches is context-dependent and debated — for some cancer types and stages mutation-based approaches perform comparably. Combination of modalities (mutations + methylation + fragmentomics) consistently outperforms single modalities. Cross-omics integration is a strength. Rapidly evolving field with large prospective validation studies ongoing.",
      "difficulty": "hard"
    },
    {
      "id": "cg_022",
      "claim": "Circulating tumor cells (CTCs) enumerated by the CellSearch platform in metastatic breast cancer provide independent prognostic information, with a threshold of 5 or more CTCs per 7.5 mL blood associated with significantly worse progression-free and overall survival.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.4,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Cristofanilli et al. (2004, New England Journal of Medicine; 2016, The Lancet Oncology) established and validated the CTC threshold in metastatic breast cancer across pooled analysis of multiple studies. CellSearch is the only FDA-cleared CTC platform. Prognostic value is well-replicated across independent cohorts. However, CTCs have not been proven to guide therapeutic decisions prospectively (SWOG S0500 trial was negative for CTC-directed therapy). CTC enumeration underestimates true circulating tumor cell burden due to EpCAM-dependent capture limitations. Limited cross-omics integration.",
      "difficulty": "medium"
    },
    {
      "id": "cg_023",
      "claim": "Homologous recombination deficiency (HRD) scores calculated from genomic scarring patterns (loss of heterozygosity, telomeric allelic imbalance, large-scale state transitions) predict PARP inhibitor sensitivity beyond BRCA1/2 mutation status, extending the targetable population in ovarian and breast cancers.",
      "domain": "cancer_genomics",
      "expected_R": 0.75,
      "expected_C": 0.4,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "Myriad myChoice HRD test (Timms et al., 2014, Breast Cancer Research) combines three genomic scar signatures. PRIMA trial (Gonzalez-Martin et al., 2019, New England Journal of Medicine) showed niraparib benefit in HRD-positive/BRCA-wildtype ovarian cancer. However, HRD score thresholds vary by platform and clinical context. 'Genomic scars' reflect historical HRD that may not persist at time of treatment if HR function is restored. Cross-omics from RAD51 foci functional assays may better capture current HR status. Some HRD-positive patients do not respond to PARP inhibitors.",
      "difficulty": "hard"
    },
    {
      "id": "cg_024",
      "claim": "Neoantigen prediction from tumor whole-exome sequencing combined with HLA typing and MHC-peptide binding algorithms can identify immunogenic mutations that drive anti-tumor T-cell responses, enabling personalized cancer vaccine development with clinical activity demonstrated in melanoma and glioblastoma trials.",
      "domain": "cancer_genomics",
      "expected_R": 0.55,
      "expected_C": 0.35,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Ott et al. (2017, Nature) and Sahin et al. (2017, Nature) demonstrated personalized neoantigen vaccines inducing neoantigen-specific T-cell responses in melanoma patients. Keskin et al. (2019, Nature) reported activity in glioblastoma. However, only a minority of predicted neoantigens actually elicit immune responses (5-10% validation rate). MHC binding prediction algorithms have significant false positive rates. Clinical benefit beyond immune response induction remains uncertain. Cross-omics from T-cell receptor sequencing and HLA-peptide mass spectrometry provide some functional validation but are technically challenging.",
      "difficulty": "hard"
    },
    {
      "id": "cg_025",
      "claim": "Tumor-infiltrating lymphocyte (TIL) density and composition, assessed by standardized histopathological scoring or deconvolution of bulk RNA-seq data, is an independent prognostic biomarker in triple-negative breast cancer and melanoma, with high TIL scores predicting improved response to immune checkpoint inhibitors.",
      "domain": "cancer_genomics",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Salgado et al. (2015, Annals of Oncology) provided standardized TIL scoring guidelines for breast cancer. Loi et al. (2019, Journal of Clinical Oncology) confirmed TIL prognostic value in TNBC. IMpassion130 exploratory analyses showed TIL-enriched tumors derived greater benefit from atezolizumab (Schmid et al., 2020, The Lancet Oncology). Cross-omics from CIBERSORTx deconvolution, single-cell RNA-seq, and multiplex IHC partially converge on TIL composition. Pathologist inter-observer variability in TIL scoring remains a limitation. Predictive (vs. prognostic) value for ICI is still being established in prospective studies.",
      "difficulty": "medium"
    },
    {
      "id": "cg_026",
      "claim": "Tumor evolution under therapeutic pressure follows predictable trajectories, with EGFR T790M gatekeeper mutations accounting for approximately 50-60% of acquired resistance to first-generation EGFR TKIs (gefitinib, erlotinib) in EGFR-mutant non-small cell lung cancer.",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.45,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Yu et al. (2013, Clinical Cancer Research) and Sequist et al. (2011, Science Translational Medicine) characterized EGFR T790M as the dominant resistance mechanism. Well-replicated across multiple studies using re-biopsy tissue and ctDNA. Third-generation EGFR TKI osimertinib (Mok et al., 2017, New England Journal of Medicine) specifically targets T790M. However, osimertinib resistance itself involves diverse mechanisms (C797S, MET amplification, small cell transformation). The 50-60% frequency is robust. Resistance mechanism landscape shifts with first-line osimertinib use.",
      "difficulty": "easy"
    },
    {
      "id": "cg_027",
      "claim": "ESR1 ligand-binding domain mutations (D538G, Y537S) are a frequent mechanism of acquired resistance to aromatase inhibitor therapy in metastatic estrogen receptor-positive breast cancer, detectable by ctDNA liquid biopsy months before clinical progression.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.4,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "Toy et al. (2013, Nature Genetics) and Robinson et al. (2013, Nature Genetics) identified ESR1 mutations in endocrine-resistant breast cancer. ctDNA detection of ESR1 mutations was demonstrated by Fribbens et al. (2016, Journal of Clinical Oncology) and Schiavon et al. (2015, Science Translational Medicine). ESR1 mutations are enriched in metastatic vs. primary tumors (30-40% vs. <5%). Oral SERD elacestrant (Bidard et al., 2022, Journal of the American Medical Association) targets ESR1-mutant tumors. Well-replicated finding with clear clinical application in treatment sequencing.",
      "difficulty": "medium"
    },
    {
      "id": "cg_028",
      "claim": "Cancer stem cells (CSCs) represent a rare, self-renewing subpopulation within tumors that exclusively drives tumor initiation, metastasis, and therapeutic resistance, and their complete eradication is both necessary and sufficient for cancer cure.",
      "domain": "cancer_genomics",
      "expected_R": 0.25,
      "expected_C": 0.2,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.45,
      "rationale": "Negative control claim with overstated framing. While CSC-like populations exist (Al-Hajj et al., 2003, Proceedings of the National Academy of Sciences; Lapidot et al., 1994, Nature), the strict hierarchical CSC model is debated. Plasticity between CSC and non-CSC states is now well-documented (Gupta et al., 2011, Cell). 'Exclusively drives' and 'necessary and sufficient' are too absolute — non-CSC cells can revert to CSC states. CSC markers (CD44, CD133, ALDH) are not universal across cancer types. Therapeutic implications of CSC targeting remain largely unrealized clinically.",
      "difficulty": "hard"
    },
    {
      "id": "cg_029",
      "claim": "Patient-derived tumor organoid models faithfully recapitulate the histological architecture, genomic landscape, and drug sensitivity profiles of their parental tumors, enabling high-throughput personalized drug screening with clinical-grade predictive accuracy for treatment selection.",
      "domain": "cancer_genomics",
      "expected_R": 0.6,
      "expected_C": 0.4,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Vlachogiannis et al. (2018, Science) demonstrated organoid drug sensitivity prediction in metastatic gastrointestinal cancers with ~80% concordance. van de Wetering et al. (2015, Cell) established colorectal cancer organoid biobanks retaining genomic features. However, 'clinical-grade predictive accuracy' overstates current evidence — prospective clinical utility trials are ongoing but not yet definitive. Organoids lack tumor microenvironment components (immune cells, stroma). Drug sensitivity assays lack standardization across laboratories. Cross-omics from genomic and transcriptomic profiling of organoids vs. parent tumors shows good but imperfect concordance.",
      "difficulty": "hard"
    },
    {
      "id": "cg_030",
      "claim": "Single-agent targeted therapy can achieve durable complete responses and functional cures in the majority of patients with metastatic solid tumors harboring actionable genomic alterations, rendering combination therapy unnecessary when the correct driver mutation is targeted.",
      "domain": "cancer_genomics",
      "expected_R": 0.15,
      "expected_C": 0.1,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.15,
      "rationale": "Negative control claim. While targeted therapies produce dramatic initial responses (BRAF inhibitors in melanoma, ALK inhibitors in NSCLC), acquired resistance develops in virtually all patients with metastatic solid tumors on single-agent therapy. Imatinib in CML is the rare exception but CML is a hematologic malignancy. Durable complete responses to single-agent targeted therapy in metastatic solid tumors are extremely rare (<5%). Combination strategies are now standard of care (BRAF+MEK, EGFR TKI+chemotherapy). The claim is demonstrably false and should receive very low scores.",
      "difficulty": "easy"
    },
    {
      "id": "cg_031",
      "claim": "IDH1 R132H and IDH2 R172K/R140Q mutations in acute myeloid leukemia and glioma produce the oncometabolite 2-hydroxyglutarate (2-HG), which inhibits alpha-ketoglutarate-dependent dioxygenases including TET2 and histone demethylases, causing epigenetic dysregulation that can be therapeutically targeted by IDH inhibitors (ivosidenib, enasidenib).",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.5,
      "expected_M": 0.85,
      "expected_X": 0.65,
      "expected_T": 0.75,
      "rationale": "Dang et al. (2009, Nature) discovered 2-HG production by mutant IDH. Figueroa et al. (2010, Cancer Cell) linked IDH mutations to DNA methylation changes via TET2 inhibition. DiNardo et al. (2018, New England Journal of Medicine) demonstrated ivosidenib clinical activity in IDH1-mutant AML. Vorasidenib showed activity in IDH-mutant glioma (Mellinghoff et al., 2023, New England Journal of Medicine). Cross-omics from metabolomics (2-HG levels), methylation arrays, and clinical response data converge. Well-validated mechanistic oncology story from bench to bedside.",
      "difficulty": "medium"
    },
    {
      "id": "cg_032",
      "claim": "DNMT3A R882 mutations are the most common DNMT3A alterations in acute myeloid leukemia, acting as dominant-negative inhibitors of DNA methyltransferase activity and serving as early founder mutations in clonal hematopoiesis that persist through treatment and relapse.",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "Ley et al. (2010, New England Journal of Medicine) identified recurrent DNMT3A mutations in AML. Russler-Germain et al. (2014, Cell Reports) demonstrated dominant-negative mechanism of R882 mutations. Shlush et al. (2014, Nature) showed DNMT3A mutations as pre-leukemic events persisting in remission HSCs. Persistence through remission is replicated across multiple AML sequencing studies (Klco et al., 2015, Journal of the American Medical Association). Cross-omics from methylation profiling and gene expression data partially support functional consequences. Stable finding over a decade of AML genomics research.",
      "difficulty": "medium"
    },
    {
      "id": "cg_033",
      "claim": "Liquid biopsy detection of minimal residual disease (MRD) through ctDNA analysis after curative-intent treatment in early-stage colorectal cancer identifies patients at high risk of recurrence with lead times of 6-12 months before radiographic detection, potentially enabling adjuvant therapy escalation or de-escalation strategies.",
      "domain": "cancer_genomics",
      "expected_R": 0.75,
      "expected_C": 0.4,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "DYNAMIC trial (Tie et al., 2022, New England Journal of Medicine) demonstrated ctDNA-guided adjuvant therapy in stage II colon cancer. Reinert et al. (2019, JAMA Oncology) showed ctDNA MRD detection precedes radiographic relapse by median 8.7 months. Replicated across independent cohorts using different ctDNA platforms (Signatera, Guardant Reveal, FoundationOne Tracker). Sensitivity depends on tumor shedding characteristics, assay sensitivity, and sampling frequency. Prospective interventional trials are ongoing to confirm clinical utility of ctDNA-guided therapy decisions.",
      "difficulty": "hard"
    },
    {
      "id": "cg_034",
      "claim": "The PCAWG (Pan-Cancer Analysis of Whole Genomes) consortium analysis of 2,658 whole cancer genomes identified non-coding driver mutations in regulatory elements including TERT promoter mutations, 3' UTR alterations, and enhancer hijacking events, demonstrating that the non-coding genome contributes significantly to cancer development beyond protein-coding mutations.",
      "domain": "cancer_genomics",
      "expected_R": 0.75,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "PCAWG Consortium (2020, Nature; Rheinbay et al., 2020, Nature) provided comprehensive non-coding driver analysis. TERT promoter mutations (Huang et al., 2013, Science) are the most validated non-coding driver. However, systematic non-coding driver discovery has high false discovery rates due to mutational heterogeneity and limited statistical power. Enhancer hijacking events (Northcott et al., 2014, Nature) are validated in specific cancer types. Cross-omics from epigenomic annotations and gene expression data support functional impact. Non-coding driver landscape is less mature than protein-coding driver catalog.",
      "difficulty": "medium"
    },
    {
      "id": "cg_035",
      "claim": "Tumor mutational signatures deconvolved from whole-genome or whole-exome sequencing data reflect the mutagenic processes active during tumor evolution, with specific signatures (SBS1/clock-like, SBS2/APOBEC, SBS4/tobacco, SBS7/UV) providing etiological information and potential therapeutic implications.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": 0.55,
      "expected_T": 0.7,
      "rationale": "Alexandrov et al. (2013, Nature; 2020, Nature) established the framework of mutational signatures from thousands of cancer genomes. COSMIC signature database is widely used and independently validated. Specific signature-etiology links are robust (SBS4/tobacco in lung, SBS7/UV in melanoma). However, signature deconvolution methods can be unstable with small mutation counts, and some signatures have uncertain etiology. Therapeutic implications (APOBEC signature and immunotherapy response) are emerging but not fully validated. Cross-omics from exposure history and clinical data provide partial validation.",
      "difficulty": "hard"
    },
    {
      "id": "cg_036",
      "claim": "MET amplification and MET exon 14 skipping mutations define a druggable oncogenic driver in non-small cell lung cancer, with selective MET inhibitors capmatinib and tepotinib achieving objective response rates of 40-70% in MET-altered NSCLC depending on alteration type and line of therapy.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.4,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "GEOMETRY mono-1 trial (Wolf et al., 2020, New England Journal of Medicine) demonstrated capmatinib activity in MET exon 14 altered NSCLC. VISION trial (Paik et al., 2020, New England Journal of Medicine) showed tepotinib efficacy. Response rates are higher in treatment-naive patients (68%) vs. previously treated (41%). MET alterations as resistance mechanism to EGFR TKIs are also well-characterized. MET amplification definition and testing standards vary across platforms. Duration of response is shorter than for ALK/ROS1 inhibitors. An emerging but validated precision oncology target.",
      "difficulty": "medium"
    },
    {
      "id": "cg_037",
      "claim": "All solid tumors exhibit a strictly linear model of metastatic dissemination, where primary tumor cells accumulate mutations to a defined threshold before acquiring metastatic competence and seeding a single distant site, followed by sequential colonization of additional organs.",
      "domain": "cancer_genomics",
      "expected_R": 0.1,
      "expected_C": 0.1,
      "expected_M": 0.3,
      "expected_X": null,
      "expected_T": 0.15,
      "rationale": "Negative control claim. The strict linear metastasis model is contradicted by extensive genomic evidence. Notta et al. (2016, Nature) showed parallel evolution in pancreatic cancer metastases. Reiter et al. (2018, Science) found polyclonal seeding of metastases. Gundem et al. (2015, Nature) demonstrated metastasis-to-metastasis spread in prostate cancer. Early dissemination before clinical detection is documented. Self-seeding of primary tumors by circulating tumor cells (Kim et al., 2009, Cell) further contradicts the linear model. The 'all solid tumors' universalism is demonstrably false.",
      "difficulty": "easy"
    },
    {
      "id": "cg_038",
      "claim": "Whole-genome doubling (WGD) occurs in approximately 30-40% of solid tumors and is associated with increased intratumor heterogeneity, tolerance of chromosomal instability, and worse clinical prognosis, potentially serving as a biomarker for therapeutic vulnerability to anti-mitotic agents.",
      "domain": "cancer_genomics",
      "expected_R": 0.7,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "Bielski et al. (2018, Nature Genetics) characterized WGD frequency and consequences across cancer types. Quinton et al. (2021, Nature) showed WGD cells tolerate chromosomal instability through p53 loss. Prognostic impact documented in multiple tumor types (NSCLC, ovarian, breast). However, the therapeutic vulnerability claim is speculative — anti-mitotic agent sensitivity in WGD tumors is not consistently demonstrated. Cross-omics from copy number, ploidy analysis, and gene expression partially support the heterogeneity association. Detection requires high-quality copy number data or flow cytometry.",
      "difficulty": "hard"
    },
    {
      "id": "cg_039",
      "claim": "Single-cell RNA sequencing of the tumor microenvironment has revealed a continuous spectrum of macrophage polarization states rather than the classical M1/M2 dichotomy, with tumor-associated macrophage transcriptomic programs correlating with patient outcomes and immunotherapy response across cancer types.",
      "domain": "cancer_genomics",
      "expected_R": 0.75,
      "expected_C": 0.5,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Mulder et al. (2021, Cell) identified a pan-cancer myeloid cell atlas from single-cell data. Cheng et al. (2021, Cell) characterized tumor-associated macrophage diversity. The M1/M2 dichotomy has been increasingly questioned by scRNA-seq data showing continuous polarization states (Xue et al., 2014, Immunity). Clinical correlations are emerging but not all studies agree on which TAM programs predict outcomes. Cross-omics from spatial transcriptomics and multiplex imaging add spatial context. The field is evolving rapidly with new data regularly updating macrophage classification schemes.",
      "difficulty": "medium"
    },
    {
      "id": "cg_040",
      "claim": "Comprehensive genomic profiling (CGP) using targeted next-generation sequencing panels (FoundationOne CDx, MSK-IMPACT) identifies at least one actionable genomic alteration in 40-60% of advanced solid tumors, though only 10-15% of patients ultimately receive matched targeted therapy and derive clinical benefit.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Zehir et al. (2017, Nature Medicine) reported MSK-IMPACT results in >10,000 patients. Frampton et al. (2013, Nature Biotechnology) validated the FoundationOne panel. The actionability gap (many actionable findings, few treated patients) is well-documented across multiple institutional precision oncology programs (SHIVA, NCI-MATCH, TAPUR). Reasons include lack of approved therapies, clinical trial access barriers, and competing standard-of-care options. The 10-15% clinical benefit rate is a sobering but reproducible finding. Evolving as more targeted therapies gain approval.",
      "difficulty": "easy"
    },
    {
      "id": "cg_041",
      "claim": "Clonal hematopoiesis driven by TET2 loss-of-function mutations increases cardiovascular disease risk independently of traditional risk factors, through enhanced IL-1beta-mediated inflammation in macrophages, as demonstrated by Mendelian randomization studies and Tet2-knockout mouse models.",
      "domain": "cancer_genomics",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "Jaiswal et al. (2017, New England Journal of Medicine) linked CHIP to cardiovascular disease risk. Fuster et al. (2017, Science) demonstrated Tet2-loss accelerated atherosclerosis in mice via NLRP3/IL-1beta pathway. Mendelian randomization analyses provide causal inference support (Bick et al., 2020, Nature). Cross-omics from human genetic, mouse model, and clinical outcome data converge. However, the specific IL-1beta mechanism may not fully explain the cardiovascular risk — TET2 loss affects multiple inflammatory pathways. CANTOS trial post-hoc analyses (Svensson et al., 2022, JAMA Cardiology) suggest anti-IL-1beta therapy may particularly benefit CHIP carriers.",
      "difficulty": "medium"
    },
    {
      "id": "cg_042",
      "claim": "FGFR2 fusions and activating mutations are therapeutic targets in intrahepatic cholangiocarcinoma, with the selective FGFR inhibitor pemigatinib achieving objective response rates of approximately 36% in FGFR2 fusion-positive patients, establishing a new molecular subtype for targeted therapy in biliary tract cancers.",
      "domain": "cancer_genomics",
      "expected_R": 0.8,
      "expected_C": 0.4,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "FIGHT-202 trial (Abou-Alfa et al., 2020, The Lancet Oncology) demonstrated pemigatinib activity in FGFR2 fusion-positive cholangiocarcinoma. Futibatinib (Goyal et al., 2023, New England Journal of Medicine) provides a second validated FGFR inhibitor. FGFR2 fusions occur in approximately 10-15% of intrahepatic cholangiocarcinoma. Acquired resistance through FGFR2 kinase domain mutations is documented. Response is specific to fusion-positive tumors — FGFR2 mutations/amplifications show lower response rates. A validated but relatively new precision oncology indication.",
      "difficulty": "medium"
    },
    {
      "id": "cg_043",
      "claim": "Immune checkpoint inhibitor therapy produces complete and durable tumor regression in virtually all patients with advanced melanoma when administered as ipilimumab plus nivolumab combination, with five-year overall survival rates approaching 90% and minimal immune-related adverse events.",
      "domain": "cancer_genomics",
      "expected_R": 0.15,
      "expected_C": 0.1,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.2,
      "rationale": "Negative control claim. CheckMate-067 (Larkin et al., 2019, New England Journal of Medicine) showed 5-year OS of 52% with ipilimumab+nivolumab, not 90%. Objective response rate is ~58%, not 'virtually all patients.' Grade 3-4 immune-related adverse events occur in approximately 59% of patients receiving combination ICI, making 'minimal adverse events' demonstrably false. Primary resistance occurs in >40% of patients. The claim grossly overstates both efficacy and safety. Any calibrated system should assign very low reproducibility scores.",
      "difficulty": "easy"
    },
    {
      "id": "cg_044",
      "claim": "RAS-MAPK pathway reactivation is the dominant mechanism of acquired resistance to BRAF inhibitors in BRAF V600E melanoma, occurring through diverse molecular routes including BRAF amplification, BRAF splice variants, MEK1/2 mutations, NRAS mutations, and receptor tyrosine kinase upregulation.",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Shi et al. (2014, Nature Communications) and Johnson et al. (2015, Cancer Discovery) comprehensively characterized BRAF inhibitor resistance mechanisms. MAPK reactivation accounts for ~70% of resistance cases across studies. The diversity of convergent resistance mechanisms supports the robustness of the MAPK dependency. Cross-omics from whole-exome sequencing, RNA-seq, and phosphoproteomics of resistant tumors converge on MAPK pathway reactivation. Rationale for combination BRAF+MEK inhibitor therapy. Resistance mechanisms beyond MAPK (PI3K/AKT pathway, phenotype switching) account for remaining cases.",
      "difficulty": "medium"
    },
    {
      "id": "cg_045",
      "claim": "Cell-free DNA methylation profiling can detect and localize cancer tissue of origin with higher accuracy than mutation-based ctDNA analysis, leveraging the tissue-specificity of DNA methylation patterns preserved in circulating cell-free DNA fragments.",
      "domain": "cancer_genomics",
      "expected_R": 0.7,
      "expected_C": 0.4,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Liu et al. (2020, Annals of Oncology) demonstrated cfDNA methylation-based multi-cancer early detection (Galleri test). Tissue-of-origin prediction accuracy exceeds 90% when cancer signal is detected. Klein et al. (2021, Annals of Oncology) validated performance in large cohorts. The advantage over mutation-based approaches for tissue-of-origin localization is supported. However, overall sensitivity for early-stage cancer detection remains modest (stage I: ~17-40% depending on cancer type). Cross-omics integration with fragmentomics and mutations improves performance. Prospective clinical utility trials (PATHFINDER, NHS-Galleri) are ongoing.",
      "difficulty": "medium"
    },
    {
      "id": "cg_046",
      "claim": "Bispecific T-cell engager (BiTE) antibodies and bispecific antibodies targeting tumor antigens and CD3 have expanded beyond hematologic malignancies into solid tumors, though efficacy in solid tumors remains limited by tumor antigen heterogeneity, immunosuppressive microenvironment, and on-target off-tumor toxicity.",
      "domain": "cancer_genomics",
      "expected_R": 0.65,
      "expected_C": 0.4,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Blinatumomab (Kantarjian et al., 2017, New England Journal of Medicine) established BiTE efficacy in B-ALL. Teclistamab in multiple myeloma (Moreau et al., 2022, New England Journal of Medicine) validated the approach in another hematologic malignancy. Solid tumor bispecific antibodies (DLL3xCD3, HER2xCD3) show preliminary activity but lower response rates than in hematologic cancers. The limitation claims (antigen heterogeneity, TME suppression) are well-supported by preclinical and clinical data. Cytokine release syndrome management remains challenging. Emerging but rapidly evolving therapeutic class.",
      "difficulty": "medium"
    },
    {
      "id": "cg_047",
      "claim": "Antibody-drug conjugates (ADCs) targeting HER2 at low expression levels, specifically trastuzumab deruxtecan (T-DXd), demonstrate clinically meaningful activity in HER2-low breast cancer (IHC 1+ or 2+/ISH-), challenging the traditional binary classification of HER2 status and expanding the treatable population.",
      "domain": "cancer_genomics",
      "expected_R": 0.85,
      "expected_C": 0.45,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "DESTINY-Breast04 trial (Modi et al., 2022, New England Journal of Medicine) demonstrated T-DXd superiority over standard chemotherapy in HER2-low metastatic breast cancer. The bystander effect of the topoisomerase I inhibitor payload enables activity despite low HER2 expression. This fundamentally changed clinical practice and HER2 testing paradigms. Replicated in multiple tumor types (DESTINY-Lung01, DESTINY-Gastric01). However, the HER2-low category introduces reproducibility challenges for pathologists. The concept is new enough that long-term temporal stability is still being established.",
      "difficulty": "easy"
    },
    {
      "id": "cg_048",
      "claim": "Pan-cancer single-cell RNA sequencing atlases have identified a conserved exhausted CD8+ T-cell program characterized by expression of TOX, PDCD1, LAG3, HAVCR2, and CTLA4 that is associated with response to immune checkpoint blockade, with TCF1+ progenitor exhausted cells being the critical population mediating immunotherapy responses.",
      "domain": "cancer_genomics",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.75,
      "expected_X": 0.6,
      "expected_T": 0.55,
      "rationale": "Zheng et al. (2021, Science) and Oliveira et al. (2022, Nature) characterized exhausted T-cell programs from pan-cancer single-cell data. TCF1+ progenitor exhausted cells as mediators of ICI response demonstrated by Sade-Feldman et al. (2018, Cell) and Miller et al. (2019, Nature Immunology). TOX as master regulator of T-cell exhaustion shown by Khan et al. (2019, Nature; Scott et al., 2019, Nature). Cross-omics from scRNA-seq, scATAC-seq, and spatial transcriptomics converge. The field is evolving rapidly with new states being described. Not all exhausted T-cell programs are equivalent across cancer types.",
      "difficulty": "hard"
    },
    {
      "id": "cg_049",
      "claim": "RB1 loss in combination with TP53 inactivation drives lineage plasticity and neuroendocrine transformation as a mechanism of acquired resistance to androgen receptor-targeted therapy in prostate cancer and EGFR TKI therapy in lung adenocarcinoma.",
      "domain": "cancer_genomics",
      "expected_R": 0.7,
      "expected_C": 0.4,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Mu et al. (2017, Science) demonstrated RB1/TP53 loss driving neuroendocrine prostate cancer transformation. Sequist et al. (2011, Science Translational Medicine) documented small cell transformation in EGFR-mutant lung cancer. Beltran et al. (2016, Nature Medicine) characterized treatment-emergent neuroendocrine prostate cancer genomics. The lineage plasticity mechanism is increasingly recognized across cancer types. Cross-omics from genomic, epigenomic (DNA methylation, chromatin accessibility), and transcriptomic data converge on the transformation program. Frequency is relatively low (10-15% of resistance cases) but clinically important.",
      "difficulty": "hard"
    },
    {
      "id": "cg_050",
      "claim": "Tumor genomic profiling by next-generation sequencing has completely replaced traditional histopathological diagnosis in clinical oncology, rendering tissue morphology assessment and immunohistochemistry unnecessary for treatment decision-making in all solid tumor types.",
      "domain": "cancer_genomics",
      "expected_R": 0.05,
      "expected_C": 0.05,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.1,
      "rationale": "Negative control claim. Histopathology remains the cornerstone of cancer diagnosis and is legally required for treatment initiation in all jurisdictions. While NGS provides critical complementary information, it does not replace morphological assessment, IHC (PD-L1, HER2, hormone receptors), or in situ hybridization. Many treatment decisions (surgery, radiation fields) depend primarily on histological and staging information. The claim is demonstrably false — genomic profiling and histopathology are complementary, not substitutive. Any well-calibrated scoring system should assign near-zero scores.",
      "difficulty": "easy"
    },
    {
      "id": "ns_001",
      "claim": "Long-term potentiation (LTP) at hippocampal CA3-CA1 synapses requires NMDA receptor activation, postsynaptic calcium influx, and CaMKII autophosphorylation for induction, with AMPA receptor trafficking to the postsynaptic density as the primary expression mechanism, representing the leading cellular model for learning and memory.",
      "domain": "neuroscience",
      "expected_R": 0.9,
      "expected_C": 0.55,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.9,
      "rationale": "Bliss and Lomo (1973, Journal of Physiology) first described hippocampal LTP. NMDA receptor dependence established by Collingridge et al. (1983, Journal of Physiology). CaMKII requirement demonstrated by Lisman et al. (2002, Nature Reviews Neuroscience). AMPA receptor trafficking as expression mechanism shown by Malinow and Malenka (2002, Annual Review of Neuroscience). One of the most replicated findings in neuroscience across thousands of laboratories. Condition-specific to specific synapse types and induction protocols. Temporal stability is exceptional — core mechanism has been consistent for four decades.",
      "difficulty": "easy"
    },
    {
      "id": "ns_002",
      "claim": "Adult hippocampal neurogenesis occurs in the human dentate gyrus throughout life, with new granule neurons being generated from neural stem cells in the subgranular zone and functionally integrating into existing circuits, contributing to pattern separation and mood regulation.",
      "domain": "neuroscience",
      "expected_R": 0.5,
      "expected_C": 0.4,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.35,
      "rationale": "Eriksson et al. (1998, Nature Medicine) first reported adult human hippocampal neurogenesis using BrdU labeling. However, Sorrells et al. (2018, Nature) found no evidence of neurogenesis in adult human hippocampus, while Boldrini et al. (2018, Cell Stem Cell) reported persistence throughout aging. The field remains deeply divided. Methodological issues including tissue fixation, antibody specificity, and postmortem interval contribute to contradictory results. Rodent evidence for functional neurogenesis is strong but human translation is contested. Cross-omics from single-nucleus RNA-seq partially supports progenitor persistence but functional integration evidence in humans is absent.",
      "difficulty": "hard"
    },
    {
      "id": "ns_003",
      "claim": "Synaptic pruning during adolescence is mediated in part by microglia-dependent complement signaling (C1q, C3), with aberrant pruning implicated in schizophrenia pathogenesis through excessive elimination of cortical synapses, as supported by genome-wide association of the C4A gene locus.",
      "domain": "neuroscience",
      "expected_R": 0.65,
      "expected_C": 0.4,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Sekar et al. (2016, Nature) identified C4A structural variants as schizophrenia risk factors. Stevens et al. (2007, Cell) demonstrated complement-mediated synaptic pruning in developing visual cortex. Schafer et al. (2012, Neuron) showed microglial complement receptor-dependent synaptic engulfment. However, the direct link from C4A variants to excessive pruning to schizophrenia pathogenesis is largely inferred rather than directly demonstrated in human tissue. Cross-omics from GWAS, mouse models, and postmortem tissue partially converge. The causal chain contains significant gaps.",
      "difficulty": "medium"
    },
    {
      "id": "ns_004",
      "claim": "Astrocytes actively modulate synaptic transmission through calcium-dependent release of gliotransmitters including glutamate, D-serine, and ATP, forming a tripartite synapse model where astrocytic signaling is essential for normal synaptic plasticity and information processing.",
      "domain": "neuroscience",
      "expected_R": 0.65,
      "expected_C": 0.45,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Araque et al. (1999, Trends in Neurosciences) proposed the tripartite synapse concept. Henneberger et al. (2010, Nature) demonstrated D-serine from astrocytes modulates LTP. However, the gliotransmission concept is debated — Fiacco and McCarthy (2018, Glia) argued that many gliotransmission findings reflect experimental artifacts (IP3R2 knockout controversy). The 'essential' claim is overstated for some synapses. Calcium signaling dynamics in astrocytes are complex and not fully understood. The field remains polarized between gliotransmission proponents and skeptics. Temporal stability is poor due to ongoing debate.",
      "difficulty": "hard"
    },
    {
      "id": "ns_005",
      "claim": "Microglia serve as the primary innate immune cells of the central nervous system, performing continuous surveillance of the brain parenchyma, synaptic pruning during development, clearance of cellular debris, and neuroinflammatory responses, with distinct transcriptomic states identified by single-cell RNA-seq across disease conditions.",
      "domain": "neuroscience",
      "expected_R": 0.85,
      "expected_C": 0.55,
      "expected_M": 0.8,
      "expected_X": 0.6,
      "expected_T": 0.7,
      "rationale": "Nimmerjahn et al. (2005, Science) demonstrated continuous microglial surveillance using in vivo two-photon imaging. Keren-Shaul et al. (2017, Cell) identified disease-associated microglia (DAM) by single-cell RNA-seq. Multiple scRNA-seq studies across Alzheimer's, ALS, and MS have characterized microglial transcriptomic states (Hammond et al., 2019, Immunity; Masuda et al., 2019, Nature). Well-replicated across species and conditions. Cross-omics from scRNA-seq, scATAC-seq, and spatial transcriptomics converge on microglial diversity. Some debate on whether ex vivo processing alters microglial states.",
      "difficulty": "easy"
    },
    {
      "id": "ns_006",
      "claim": "Oligodendrocyte precursor cells (OPCs) represent the largest proliferative cell population in the adult brain and contribute to adaptive myelination in response to experience and learning, with activity-dependent myelination of active axons enhancing circuit function and cognitive performance.",
      "domain": "neuroscience",
      "expected_R": 0.7,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "McKenzie et al. (2014, Science) demonstrated that new oligodendrocyte formation is required for motor learning. Gibson et al. (2014, Science) showed optogenetic neuronal activity promotes oligodendrogenesis and myelination. OPCs as largest proliferative CNS population established by Dawson et al. (2003, Molecular and Cellular Neuroscience). Adaptive myelination concept well-supported in rodent models (Steadman et al., 2020, Nature Neuroscience). Human evidence is more limited, relying on diffusion MRI as a proxy for myelination. The field is evolving rapidly with increasing recognition of myelin plasticity.",
      "difficulty": "medium"
    },
    {
      "id": "ns_007",
      "claim": "The blood-brain barrier (BBB) is formed by specialized brain endothelial cells connected by tight junctions (claudin-5, occludin, ZO-1), with pericyte coverage and astrocytic endfeet providing structural and signaling support, and BBB dysfunction contributes to neurodegeneration in Alzheimer's disease through impaired amyloid-beta clearance.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "BBB cellular architecture is well-established (Abbott et al., 2010, Neurobiology of Disease). Pericyte requirement demonstrated by Armulik et al. (2010, Nature) and Daneman et al. (2010, Nature). BBB breakdown in AD: Montagne et al. (2015, Neuron) showed pericyte degeneration in APOE4 carriers. Sweeney et al. (2018, Nature Reviews Neurology) reviewed BBB dysfunction in neurodegeneration. Cross-omics from transcriptomic profiling of BBB cells, imaging (DCE-MRI), and CSF biomarkers converge. The causal role of BBB dysfunction in AD pathogenesis (vs. consequence) is debated.",
      "difficulty": "medium"
    },
    {
      "id": "ns_008",
      "claim": "Neuroinflammation, characterized by microglial activation, astrogliosis, and elevated pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), is a common pathological feature across neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS, contributing to disease progression through both cell-autonomous and non-cell-autonomous mechanisms.",
      "domain": "neuroscience",
      "expected_R": 0.85,
      "expected_C": 0.55,
      "expected_M": 0.75,
      "expected_X": 0.6,
      "expected_T": 0.75,
      "rationale": "Heneka et al. (2015, The Lancet Neurology) reviewed neuroinflammation across neurodegenerative diseases. TREM2 variants as AD risk factors (Guerreiro et al., 2013, New England Journal of Medicine) directly implicate microglial function. PET imaging with TSPO ligands confirms microglial activation in vivo across diseases. However, whether neuroinflammation is primary driver or secondary response remains debated for most conditions. Anti-inflammatory clinical trials have generally failed. Cross-omics from GWAS, transcriptomics, proteomics, and imaging converge. Well-replicated descriptive finding but mechanistic causality is incompletely established.",
      "difficulty": "medium"
    },
    {
      "id": "ns_009",
      "claim": "The amyloid cascade hypothesis posits that amyloid-beta peptide accumulation initiates Alzheimer's disease pathogenesis, driving tau hyperphosphorylation, neuroinflammation, synaptic loss, and neurodegeneration, with anti-amyloid antibodies (lecanemab, donanemab) providing clinical validation through modest but statistically significant slowing of cognitive decline.",
      "domain": "neuroscience",
      "expected_R": 0.55,
      "expected_C": 0.4,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.4,
      "rationale": "Hardy and Higgins (1992, Science) proposed the amyloid cascade hypothesis. Lecanemab (van Dyck et al., 2023, New England Journal of Medicine) slowed decline by 27% over 18 months. Donanemab (Sims et al., 2023, Journal of the American Medical Association) showed similar magnitude of benefit. These provide some clinical validation but 'modest' benefit raises questions about amyloid's centrality. Earlier anti-amyloid drugs failed (solanezumab, aducanumab controversy). Amyloid-independent tau pathology, neuroinflammation, and synaptic dysfunction may be equally important. Cross-omics partially supportive but the hypothesis has been modified significantly over 30 years.",
      "difficulty": "hard"
    },
    {
      "id": "ns_010",
      "claim": "Tau protein propagation follows a prion-like template-directed misfolding mechanism, spreading through synaptically connected brain regions in a stereotypical pattern (Braak staging) in Alzheimer's disease, with tau PET imaging confirming in vivo spread patterns that correlate with neurodegeneration and cognitive decline.",
      "domain": "neuroscience",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Braak and Braak (1991, Acta Neuropathologica) described stereotypical tau staging. De Calignon et al. (2012, Neuron) demonstrated trans-synaptic tau spread in mouse models. Tau PET imaging (Ossenkoppele et al., 2022, Nature Medicine) confirmed Braak staging patterns in vivo. Clavaguera et al. (2009, Nature Cell Biology) showed prion-like tau transmission. The prion-like model is well-replicated in animal models. Human evidence from tau PET is correlative — direct demonstration of template-directed misfolding in human brain is limited. Cross-omics from neuropathology, PET imaging, and CSF biomarkers converge.",
      "difficulty": "medium"
    },
    {
      "id": "ns_011",
      "claim": "APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease, increasing risk 3-4 fold for heterozygous carriers and 8-15 fold for homozygous carriers, through mechanisms including impaired amyloid-beta clearance, exacerbated tau pathology, and compromised blood-brain barrier integrity.",
      "domain": "neuroscience",
      "expected_R": 0.95,
      "expected_C": 0.55,
      "expected_M": 0.9,
      "expected_X": 0.65,
      "expected_T": 0.9,
      "rationale": "Corder et al. (1993, Science) identified APOE4 as AD risk factor. Risk magnitudes are replicated across dozens of GWAS and cohort studies globally (Lambert et al., 2013, Nature Genetics). Mechanistic studies span amyloid clearance (Castellano et al., 2011, Science Translational Medicine), tau (Shi et al., 2017, Nature), and BBB (Montagne et al., 2020, Nature). Cross-omics from genetics, neuropathology, neuroimaging, and CSF biomarkers strongly converge. One of the most robust and replicated findings in neurogenetics. Risk magnitude varies somewhat by ethnicity and sex.",
      "difficulty": "easy"
    },
    {
      "id": "ns_012",
      "claim": "TREM2 loss-of-function variants (R47H, R62H) increase Alzheimer's disease risk with effect sizes comparable to APOE4 heterozygosity, implicating microglial phagocytic function and lipid metabolism as critical AD pathogenic mechanisms and identifying microglia as potential therapeutic targets.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.45,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Guerreiro et al. (2013, New England Journal of Medicine) and Jonsson et al. (2013, New England Journal of Medicine) identified TREM2 R47H as AD risk variant (OR ~2-4). Keren-Shaul et al. (2017, Cell) showed TREM2 is required for disease-associated microglia (DAM) transition. Nugent et al. (2020, Neuron) demonstrated TREM2 regulation of microglial lipid metabolism. Replicated across multiple GWAS and functional studies. Cross-omics from genetics, scRNA-seq, and CSF sTREM2 levels converge. Therapeutic anti-TREM2 antibodies are in clinical trials. Effect size comparable to single APOE4 allele but APOE4 homozygosity risk is higher.",
      "difficulty": "medium"
    },
    {
      "id": "ns_013",
      "claim": "Alpha-synuclein aggregation and Lewy body formation are central to Parkinson's disease pathogenesis, with SNCA gene mutations and multiplications causing familial PD, and alpha-synuclein propagation following a prion-like spread pattern from the gut to the brain via the vagus nerve (Braak hypothesis).",
      "domain": "neuroscience",
      "expected_R": 0.7,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "Polymeropoulos et al. (1997, Science) identified SNCA mutations in familial PD. Braak et al. (2003, Neurobiology of Aging) proposed caudal-to-rostral spread. Kim et al. (2019, Neuron) demonstrated gut-to-brain alpha-synuclein spread via vagus nerve in mice. Vagotomy epidemiological studies (Svensson et al., 2015, Annals of Neurology) provide indirect support. However, not all PD patients follow Braak staging, and some have brain-first rather than body-first pathology (Borghammer et al., 2020, Journal of Parkinson's Disease). Cross-omics from genetics, neuropathology, and imaging converge partially. The gut-brain hypothesis is compelling but not universal.",
      "difficulty": "hard"
    },
    {
      "id": "ns_014",
      "claim": "LRRK2 G2019S is the most common genetic cause of both familial and sporadic Parkinson's disease, with kinase activity inhibitors (DNL201, BIIB122) now in clinical development based on the hypothesis that LRRK2 hyperactivation drives lysosomal dysfunction and alpha-synuclein accumulation in dopaminergic neurons.",
      "domain": "neuroscience",
      "expected_R": 0.75,
      "expected_C": 0.4,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "Paisan-Ruiz et al. (2004, Neuron) and Zimprich et al. (2004, Neuron) identified LRRK2 mutations in familial PD. LRRK2 G2019S frequency varies by population (1-2% sporadic PD, up to 40% in North African Berbers). Kinase gain-of-function mechanism well-characterized (West et al., 2005, Proceedings of the National Academy of Sciences). LRRK2 kinase inhibitor clinical trials are early-phase (Denali Therapeutics, Biogen). Lysosomal dysfunction link supported by Rab GTPase phosphorylation studies (Steger et al., 2016, eLife). However, incomplete penetrance (~30-70% by age 80) complicates the causal narrative.",
      "difficulty": "medium"
    },
    {
      "id": "ns_015",
      "claim": "GBA1 heterozygous mutations (N370S, L444P) represent the most common genetic risk factor for Parkinson's disease, increasing risk 5-10 fold, through mechanisms involving impaired glucocerebrosidase activity, lysosomal dysfunction, and enhanced alpha-synuclein aggregation.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.45,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "Sidransky et al. (2009, New England Journal of Medicine) established GBA1 as PD risk factor in a multicenter study of >5,000 patients. Risk magnitude replicated across populations. Mazzulli et al. (2011, Cell) demonstrated that reduced GCase activity promotes alpha-synuclein accumulation. Ambroxol (Mullin et al., 2020, JAMA Neurology) and venglustat clinical trials target GBA-PD pathway. Cross-omics from genetics, enzyme activity assays, and lipidomics partially converge. Homozygous GBA1 mutations cause Gaucher disease, establishing clear biological function. Penetrance for PD in heterozygous carriers is incomplete (~10-30% by age 80).",
      "difficulty": "medium"
    },
    {
      "id": "ns_016",
      "claim": "Optogenetic manipulation of genetically defined neuronal populations has demonstrated that activation of hippocampal CA1 place cells is sufficient to induce artificial fear memory recall, and that silencing specific engram cells prevents memory retrieval, providing direct evidence for the engram theory of memory storage.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.45,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "Liu et al. (2012, Nature) demonstrated optogenetic activation of dentate gyrus engram cells induces fear memory recall. Ramirez et al. (2013, Science) created false memories by reactivating engram cells in a different context. Tonegawa group has systematically established engram cell sufficiency and necessity (Ryan et al., 2015, Science). Well-replicated across multiple laboratories using different optogenetic tools (ChR2, C1V1). However, studies are limited to rodent fear conditioning paradigms. Translation to human memory is inferred. The simplicity of fear conditioning may not capture complex memory processes.",
      "difficulty": "easy"
    },
    {
      "id": "ns_017",
      "claim": "Brain organoids (cerebral organoids) generated from human induced pluripotent stem cells recapitulate key features of human cortical development including progenitor zone organization, neuronal migration, and layer-specific neuronal identity, enabling the study of human-specific neurodevelopmental processes and disease modeling for microcephaly, autism, and Zika virus infection.",
      "domain": "neuroscience",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Lancaster et al. (2013, Nature) generated cerebral organoids recapitulating cortical development. Quadrato et al. (2017, Nature) showed organoid single-cell diversity. Qian et al. (2016, Cell) modeled Zika microcephaly. Organoid variability between batches and protocols is a significant limitation (Velasco et al., 2019, Nature). Organoids lack vascular, immune, and mature glial components. Maturation is limited compared to fetal brain. Cross-omics from scRNA-seq comparisons to fetal brain show partial but incomplete transcriptomic concordance. The field is evolving rapidly with assembloid and vascularized organoid approaches.",
      "difficulty": "medium"
    },
    {
      "id": "ns_018",
      "claim": "Single-cell and single-nucleus RNA sequencing of the human brain has revealed a far greater diversity of neuronal and glial cell types than previously recognized by morphological and electrophysiological classification, with the Allen Brain Cell Atlas cataloging over 3,000 transcriptomically distinct cell types across the adult human brain.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": 0.6,
      "expected_T": 0.6,
      "rationale": "BRAIN Initiative Cell Census Network (Siletti et al., 2023, Science) cataloged >3,000 cell clusters from >3 million nuclei across the adult human brain. Tasic et al. (2018, Nature) established mouse cortical cell type taxonomy. Lake et al. (2016, Science) and Hodge et al. (2019, Nature) characterized human cortical types. Cross-omics validation from Patch-seq (electrophysiology + transcriptomics) and spatial transcriptomics partially confirm types. However, the distinction between 'cell types' and 'cell states' is debated. Technical variables (dissociation artifacts, sequencing depth) influence cluster resolution. The exact number of types depends on clustering parameters.",
      "difficulty": "medium"
    },
    {
      "id": "ns_019",
      "claim": "The gut-brain axis, mediated by the vagus nerve, enteric nervous system, microbial metabolites (short-chain fatty acids, tryptophan metabolites), and immune signaling, influences brain function and behavior, with germ-free mouse studies showing altered anxiety-like behavior, stress responses, and neurotransmitter levels compared to conventionally colonized controls.",
      "domain": "neuroscience",
      "expected_R": 0.7,
      "expected_C": 0.4,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Cryan and Dinan (2012, Nature Reviews Neuroscience) reviewed the microbiome-gut-brain axis. Sudo et al. (2004, Journal of Physiology) showed altered stress responses in germ-free mice. Braniste et al. (2014, Science Translational Medicine) demonstrated microbiome effects on BBB. Short-chain fatty acid effects on microglia shown by Erny et al. (2015, Nature Neuroscience). Well-replicated in germ-free mouse models. However, germ-free conditions produce many systemic abnormalities beyond brain effects. Human translation from rodent gut-brain axis studies is limited. Cross-omics from metabolomics and transcriptomics partially support but causal mechanisms remain partially defined.",
      "difficulty": "hard"
    },
    {
      "id": "ns_020",
      "claim": "Sleep is essential for memory consolidation, with slow-wave sleep facilitating hippocampal-cortical dialogue through sharp-wave ripple events and sleep spindle-slow oscillation coupling, enabling systems-level memory consolidation by replaying and transferring hippocampal representations to neocortical long-term storage.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "Diekelmann and Born (2010, Nature Reviews Neuroscience) reviewed sleep and memory consolidation. Wilson and McNaughton (1994, Science) first demonstrated hippocampal replay during sleep. Staresina et al. (2015, Nature Neuroscience) showed sleep spindle-ripple coupling in humans. Girardeau et al. (2009, Nature Neuroscience) demonstrated that disrupting ripples impairs memory consolidation. Well-replicated across species (rodents and humans) and memory paradigms. Methodologically strong combining electrophysiology, fMRI, and behavioral testing. The precise mechanism of systems consolidation is still debated (complementary learning systems vs. synaptic homeostasis).",
      "difficulty": "easy"
    },
    {
      "id": "ns_021",
      "claim": "Circadian clock genes (BMAL1, CLOCK, PER, CRY) in the suprachiasmatic nucleus (SCN) of the hypothalamus generate approximately 24-hour transcription-translation feedback loop oscillations that serve as the master circadian pacemaker, with SCN lesions abolishing circadian behavioral rhythms in mammals.",
      "domain": "neuroscience",
      "expected_R": 0.95,
      "expected_C": 0.55,
      "expected_M": 0.9,
      "expected_X": null,
      "expected_T": 0.9,
      "rationale": "Ralph et al. (1990, Science) demonstrated SCN transplant restores circadian rhythms. Core clock gene transcription-translation feedback loop established by Reppert and Weaver (2002, Nature). BMAL1/CLOCK heterodimer transcriptional regulation of PER/CRY is one of the most well-characterized molecular oscillators. SCN lesion studies consistently abolish circadian locomotor rhythms across mammalian species. Replicated across dozens of laboratories over decades. The SCN as master clock is modulated by peripheral oscillators in other tissues. Nobel Prize awarded for circadian mechanism discovery (2017). Exceptionally stable and well-replicated finding.",
      "difficulty": "easy"
    },
    {
      "id": "ns_022",
      "claim": "Pain signaling involves peripheral nociceptor activation through TRPV1 (capsaicin receptor) and TRPA1 channels, transmission via A-delta and C fibers to dorsal horn neurons, and ascending pathways to thalamus and cortex, with opioid receptors (mu, delta, kappa) modulating pain at multiple levels of this circuit and chronic pain involving central sensitization and glial activation.",
      "domain": "neuroscience",
      "expected_R": 0.85,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.85,
      "rationale": "Caterina et al. (1997, Nature) cloned TRPV1 as the capsaicin/heat receptor (Nobel Prize to David Julius, 2021). The gate control theory (Melzack and Wall, 1965, Science) established the framework for pain modulation. Opioid receptor cloning and pharmacology are well-established (Kieffer, 1999, Trends in Pharmacological Sciences). Central sensitization concept by Woolf (1983, Nature). Glial activation in chronic pain demonstrated by Watkins et al. (2001, Trends in Neurosciences). Comprehensive pain signaling framework is well-replicated. Individual components vary in certainty but overall circuit is robust.",
      "difficulty": "easy"
    },
    {
      "id": "ns_023",
      "claim": "Neurovascular coupling ensures that regional cerebral blood flow matches local neuronal metabolic demand within seconds, mediated by astrocytic endfoot calcium signaling, neuronal nitric oxide release, and prostaglandin signaling, forming the physiological basis for functional MRI (fMRI) BOLD signal interpretation.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Attwell et al. (2010, Nature) reviewed neurovascular coupling mechanisms. Iadecola (2017, Neuron) comprehensively described the neurovascular unit. Astrocytic calcium-dependent vascular regulation demonstrated by Takano et al. (2006, Nature Neuroscience). Neuronal NOS and COX-2 contributions well-established. BOLD signal interpretation assumptions reviewed by Logothetis (2008, Nature). The general principle is well-replicated. However, precise cellular mechanisms remain debated — the relative contributions of neurons, astrocytes, and pericytes to blood flow regulation vary by brain region and stimulus type. NVC dysfunction in disease states (AD, hypertension) complicates interpretation.",
      "difficulty": "medium"
    },
    {
      "id": "ns_024",
      "claim": "Mirror neurons, originally discovered in macaque premotor cortex (area F5), discharge both when an animal performs a specific action and when it observes the same action performed by another individual, and an analogous mirror neuron system in humans underlies action understanding, empathy, and language evolution.",
      "domain": "neuroscience",
      "expected_R": 0.55,
      "expected_C": 0.35,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.45,
      "rationale": "Gallese et al. (1996, Brain) and Rizzolatti et al. (1996, Cognitive Brain Research) discovered mirror neurons in macaque. Mukamel et al. (2010, Current Biology) reported mirror-like neurons in humans during neurosurgery. However, the sweeping claims about empathy and language evolution (Rizzolatti and Craighero, 2004, Annual Review of Neuroscience) are poorly supported and heavily criticized (Hickok, 2009, Journal of Cognitive Neuroscience). fMRI evidence for human mirror system is indirect and subject to alternative interpretations. The original macaque finding is solid but the theoretical extrapolations are overextended. Temporal stability low due to shifting field opinion.",
      "difficulty": "hard"
    },
    {
      "id": "ns_025",
      "claim": "Adult brain plasticity, including experience-dependent cortical map reorganization, occurs throughout the lifespan and can be harnessed for rehabilitation after stroke and traumatic brain injury, with constraint-induced movement therapy and transcranial magnetic stimulation demonstrating neuroplasticity-based functional recovery in clinical trials.",
      "domain": "neuroscience",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.7,
      "rationale": "Merzenich et al. (1984, Journal of Comparative Neurology) demonstrated adult cortical map plasticity. Taub et al. (2002, Stroke) established constraint-induced movement therapy for stroke recovery. TMS therapeutic effects reviewed by Lefaucheur et al. (2014, Clinical Neurophysiology). Adult plasticity is well-replicated across sensory modalities and species. However, the degree of functional recovery after injury is highly variable and often modest. Neuroplasticity-based interventions show statistically significant but clinically limited improvements. Individual response variability is large. Effect sizes in clinical trials are moderate.",
      "difficulty": "medium"
    },
    {
      "id": "ns_026",
      "claim": "The default mode network (DMN), comprising medial prefrontal cortex, posterior cingulate cortex, angular gyrus, and medial temporal regions, is consistently active during rest and self-referential thought, deactivated during externally directed tasks, and shows disrupted connectivity in Alzheimer's disease, schizophrenia, and autism spectrum disorder.",
      "domain": "neuroscience",
      "expected_R": 0.85,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "Raichle et al. (2001, Proceedings of the National Academy of Sciences) defined the default mode network. Greicius et al. (2004, Proceedings of the National Academy of Sciences) showed DMN disruption in AD. DMN identification is highly reproducible across fMRI studies, scanner platforms, and populations. The functional interpretation (self-referential thought, mind-wandering) is supported but less definitive. DMN disruption in multiple neuropsychiatric conditions is well-replicated (Whitfield-Gabrieli and Ford, 2012, Annual Review of Clinical Psychology). Temporal stability is high for the anatomical description and task-deactivation finding.",
      "difficulty": "easy"
    },
    {
      "id": "ns_027",
      "claim": "mTOR pathway hyperactivation drives neurodegeneration in multiple conditions including tuberous sclerosis complex, focal cortical dysplasia, and age-related neurodegenerative diseases, with rapamycin and rapalogs showing neuroprotective effects in animal models through restoration of autophagy and reduction of aberrant protein synthesis.",
      "domain": "neuroscience",
      "expected_R": 0.7,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "TSC1/TSC2 mutations causing mTOR hyperactivation are well-established in tuberous sclerosis (Crino et al., 2006, New England Journal of Medicine). Rapamycin neuroprotection demonstrated in AD mouse models (Spilman et al., 2010, PLoS ONE) and other neurodegeneration models. Caccamo et al. (2010, Journal of Biological Chemistry) showed mTOR reduction decreases tau. However, mTOR has complex roles in neurons — complete inhibition is detrimental. Clinical translation from animal models is limited. Everolimus is FDA-approved for TSC-associated SEGA. Cross-omics from phosphoproteomics and transcriptomics support pathway involvement.",
      "difficulty": "medium"
    },
    {
      "id": "ns_028",
      "claim": "Dopamine signaling in the mesolimbic pathway (ventral tegmental area to nucleus accumbens) encodes reward prediction error — the difference between expected and received reward — as demonstrated by single-unit recordings in primates and confirmed by human fMRI studies, forming the computational basis for reinforcement learning in the brain.",
      "domain": "neuroscience",
      "expected_R": 0.85,
      "expected_C": 0.5,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "Schultz et al. (1997, Science) established reward prediction error coding by dopamine neurons. Rescorla-Wagner model correspondence confirmed by Montague et al. (1996, Journal of Neuroscience). Human fMRI studies replicate RPE signals in ventral striatum (O'Doherty et al., 2003, Science). Optogenetic validation in rodents (Steinberg et al., 2013, Nature Neuroscience). One of the most influential and replicated findings in systems neuroscience. Condition-specific: dopamine also encodes aversion, salience, and novelty beyond pure reward. Temporal stability is high for the core RPE finding spanning three decades.",
      "difficulty": "easy"
    },
    {
      "id": "ns_029",
      "claim": "Selective serotonin reuptake inhibitors (SSRIs) exert their antidepressant effects primarily through acute blockade of the serotonin transporter (SERT), leading to increased synaptic serotonin levels, with the therapeutic delay of 2-4 weeks reflecting slow desensitization of autoreceptors and downstream neuroplastic changes including BDNF upregulation and hippocampal neurogenesis.",
      "domain": "neuroscience",
      "expected_R": 0.65,
      "expected_C": 0.45,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "SERT blockade mechanism is well-established pharmacologically. The therapeutic delay explanation involving autoreceptor desensitization (Blier et al., 1998, Journal of Clinical Psychopharmacology) and BDNF/neuroplasticity (Duman and Aghajanian, 2012, Science) is the prevailing model. However, the serotonin hypothesis of depression itself has been questioned (Moncrieff et al., 2022, Molecular Psychiatry). SSRI efficacy vs. placebo effect size is debated (Cipriani et al., 2018, The Lancet). Neurogenesis contribution is supported in rodents but unconfirmed in humans. Cross-omics from PET imaging, CSF monoamines, and gene expression partially support. The mechanistic model is incomplete.",
      "difficulty": "hard"
    },
    {
      "id": "ns_030",
      "claim": "Ketamine produces rapid-acting antidepressant effects within hours through NMDA receptor blockade leading to a burst of AMPA receptor-mediated synaptic transmission, BDNF release, mTORC1 activation, and rapid synaptogenesis in the prefrontal cortex, fundamentally challenging the monoamine hypothesis of depression.",
      "domain": "neuroscience",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "Berman et al. (2000, Biological Psychiatry) first demonstrated rapid ketamine antidepressant effect. Li et al. (2010, Science) elucidated mTORC1 and synaptogenesis mechanism. Zanos et al. (2016, Nature) proposed hydroxynorketamine as active metabolite (debated). FDA approved esketamine (Spravato) nasal spray (2019). Rapid onset effect is well-replicated across multiple RCTs. However, the precise mechanism remains debated — NMDA blockade, AMPA throughput, opioid system involvement (Williams et al., 2018, American Journal of Psychiatry), and other pathways may contribute. Cross-omics from preclinical models partially validated in human CSF studies.",
      "difficulty": "hard"
    },
    {
      "id": "ns_031",
      "claim": "Traumatic brain injury (TBI) biomarkers in blood, including glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCH-L1), neurofilament light chain (NfL), and tau, can detect brain injury severity and predict outcomes, with GFAP and UCH-L1 receiving FDA clearance for ruling out intracranial lesions on CT in mild TBI patients.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.45,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "FDA cleared Banyan BTI (GFAP + UCH-L1) test in 2018 based on the ALERT-TBI study (Bazarian et al., 2018, The Lancet Neurology). NfL as TBI biomarker demonstrated by Shahim et al. (2020, JAMA Neurology) in multiple cohorts. TRACK-TBI consortium (Yue et al., 2019, The Lancet Neurology) validated blood biomarker performance in large prospective cohort. Well-replicated for moderate-severe TBI; performance in mild TBI/concussion is more variable. Biomarker kinetics (peak timing, half-life) differ between markers. Outcome prediction improves with multi-marker panels. Standardization of assay platforms remains an ongoing challenge.",
      "difficulty": "medium"
    },
    {
      "id": "ns_032",
      "claim": "Cerebral organoid models recapitulate spontaneous oscillatory electrical activity resembling preterm EEG patterns, exhibit neuronal network synchronization, and can model gene-environment interactions in neurodevelopmental disorders, though they lack vascular, immune, and mature glial components found in the developing human brain.",
      "domain": "neuroscience",
      "expected_R": 0.65,
      "expected_C": 0.4,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Trujillo et al. (2019, Cell Stem Cell) reported oscillatory activity in cerebral organoids resembling preterm neonatal EEG. However, this finding generated controversy regarding whether organoid activity truly recapitulates developmental patterns or reflects generic network properties of connected neurons (Muotri et al. response in Quadrato et al., 2017, Nature). Organoid-to-organoid variability in electrical activity is substantial. The acknowledged limitations (no vasculature, immune cells, limited glia) significantly constrain disease modeling fidelity. Cross-omics from scRNA-seq and MEA electrophysiology partially converge. Assembloid approaches are addressing some limitations.",
      "difficulty": "hard"
    },
    {
      "id": "ns_033",
      "claim": "Neural correlates of consciousness can be localized to specific brain structures, with the posterior cortical hot zone (temporo-parieto-occipital cortex) being the primary neural substrate for conscious experience, as supported by lesion studies, intracranial stimulation, and adversarial collaboration between integrated information theory (IIT) and global neuronal workspace theory (GNWT).",
      "domain": "neuroscience",
      "expected_R": 0.5,
      "expected_C": 0.35,
      "expected_M": 0.6,
      "expected_X": null,
      "expected_T": 0.4,
      "rationale": "Koch et al. (2016, Nature Reviews Neuroscience) proposed the posterior hot zone as primary consciousness substrate. The Templeton Foundation adversarial collaboration (Melloni et al., 2021, preregistered protocol) tested IIT vs. GNWT predictions, with initial results neither fully supporting nor refuting either theory (reported 2023). Lesion data from Boly et al. (2017, Science) support posterior cortex involvement. However, consciousness neuroscience remains deeply fragmented theoretically. Prefrontal cortex role is debated between theories. Methodological challenges in studying consciousness are formidable. The field lacks consensus on fundamental definitions.",
      "difficulty": "hard"
    },
    {
      "id": "ns_034",
      "claim": "Human adults regularly generate new neurons in the hippocampus at a rate comparable to that observed in rodents, with these adult-born neurons playing critical roles in pattern separation, mood regulation, and cognitive flexibility throughout the entire human lifespan including advanced old age.",
      "domain": "neuroscience",
      "expected_R": 0.25,
      "expected_C": 0.2,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.25,
      "rationale": "Negative control claim. While rodent adult hippocampal neurogenesis is well-established (van Praag et al., 2002, Nature), human adult neurogenesis is deeply contested. Sorrells et al. (2018, Nature) found no evidence for adult neurogenesis in human hippocampus, directly contradicting Boldrini et al. (2018, Cell Stem Cell). The claim of 'rate comparable to rodents' is not supported by even the most optimistic human estimates. Functional roles (pattern separation, mood) are extrapolated from rodent data. The 'throughout the entire lifespan' and 'advanced old age' claims are especially poorly supported. This should be scored as an overstatement.",
      "difficulty": "easy"
    },
    {
      "id": "ns_035",
      "claim": "Chronic social stress in rodent models induces depression-like behavioral phenotypes (anhedonia, social withdrawal, helplessness) accompanied by dendritic atrophy in medial prefrontal cortex and hippocampus, reduced BDNF expression, HPA axis dysregulation, and neuroinflammatory changes, with these effects being partially reversible by antidepressant treatment.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.75,
      "rationale": "Chronic social defeat stress model is one of the most well-validated depression models (Golden et al., 2011, Nature Protocols). Dendritic atrophy in PFC documented by Radley et al. (2006, Journal of Neuroscience) and hippocampus by McEwen (2007, Dialogues in Clinical Neuroscience). BDNF reduction in hippocampus (Duman and Monteggia, 2006, Biological Psychiatry) and HPA axis changes are well-replicated. Antidepressant reversal of behavioral and structural deficits shown across multiple drug classes. Cross-omics from transcriptomics and behavioral assays converge. However, construct validity of rodent depression models for human MDD is debated. Individual vulnerability/resilience is increasingly recognized.",
      "difficulty": "medium"
    },
    {
      "id": "ns_036",
      "claim": "Focused ultrasound combined with microbubbles can transiently and safely open the blood-brain barrier in targeted brain regions, enabling delivery of therapeutic antibodies, gene therapy vectors, and chemotherapeutic agents to the CNS, with Phase I/II clinical trials demonstrating feasibility in Alzheimer's disease and brain tumor patients.",
      "domain": "neuroscience",
      "expected_R": 0.7,
      "expected_C": 0.4,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.55,
      "rationale": "Hynynen et al. (2001, Radiology) demonstrated focused ultrasound BBB opening in animal models. Lipsman et al. (2018, Nature Communications) reported first-in-human FUS BBB opening in AD patients. Mainprize et al. (2019, Scientific Reports) demonstrated BBB opening for chemotherapy delivery in brain tumor patients. The approach is reproducible in animal models and early human trials show feasibility. Safety profiles are encouraging but long-term consequences of repeated BBB opening are unknown. Drug delivery enhancement magnitude varies by agent size and tissue characteristics. The field is transitioning from feasibility to efficacy testing.",
      "difficulty": "hard"
    },
    {
      "id": "ns_037",
      "claim": "Single-cell transcriptomics of the Alzheimer's disease brain has revealed disease-associated cell states across all major cell types, including disease-associated microglia (DAM), disease-associated astrocytes (DAA), and oligodendrocyte lineage changes, with TREM2-dependent microglial activation being a critical early response to amyloid pathology.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.45,
      "expected_M": 0.8,
      "expected_X": 0.6,
      "expected_T": 0.55,
      "rationale": "Keren-Shaul et al. (2017, Cell) identified DAM by scRNA-seq. Habib et al. (2020, Nature Neuroscience) identified DAA. Mathys et al. (2019, Nature) profiled AD brain at single-cell resolution. TREM2 dependence of DAM transition shown in Trem2 knockout mice by Keren-Shaul et al. Replicated across multiple cohorts and mouse models. Cross-omics from scRNA-seq, spatial transcriptomics, and CSF proteomics converge. However, postmortem tissue artifacts and ex vivo processing effects on microglial states are a concern (Marsh et al., 2022, Nature Neuroscience). The functional significance of disease-associated states is still being established.",
      "difficulty": "medium"
    },
    {
      "id": "ns_038",
      "claim": "Brain-computer interfaces (BCIs) using intracortical microelectrode arrays can decode speech intentions from motor cortex neural activity in paralyzed patients, achieving word error rates below 25% for large vocabulary tasks, representing a transformative assistive technology for locked-in patients.",
      "domain": "neuroscience",
      "expected_R": 0.65,
      "expected_C": 0.35,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Willett et al. (2023, Nature) demonstrated high-performance speech BCI achieving 9.1% word error rate in an ALS patient. Moses et al. (2021, New England Journal of Medicine) showed 50-word vocabulary speech neuroprosthesis from a stroke patient. Metzger et al. (2023, Nature) decoded speech from a participant who could not speak. Results are remarkable but limited to single or very few participants per study. Electrode longevity, signal stability over years, and generalization across patients are open questions. The field is advancing rapidly but clinical deployment is nascent. Individual patient variability in decoding performance is significant.",
      "difficulty": "hard"
    },
    {
      "id": "ns_039",
      "claim": "Anxiety disorders involve hyperactivation of the amygdala and dysregulated connectivity with the prefrontal cortex, with pharmacological interventions (benzodiazepines targeting GABA-A receptors, SSRIs) and cognitive behavioral therapy (CBT) both producing measurable changes in amygdala-PFC circuit function, as demonstrated by pre-post treatment fMRI studies.",
      "domain": "neuroscience",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Etkin and Wager (2007, American Journal of Psychiatry) meta-analyzed amygdala hyperactivation in anxiety. Goldin et al. (2012, JAMA Psychiatry) showed CBT reduces amygdala reactivity. Paulus and Stein (2006, Biological Psychiatry) reviewed amygdala-PFC circuitry in anxiety. Well-replicated across fMRI studies. However, amygdala-PFC circuit dysfunction is not specific to anxiety — similar patterns appear in depression, PTSD, and other conditions. Treatment-related fMRI changes are correlational and effect sizes vary across studies. Individual variability in neural treatment response is large. The circuit model simplifies more distributed network involvement.",
      "difficulty": "medium"
    },
    {
      "id": "ns_040",
      "claim": "Parkinson's disease motor symptoms are caused exclusively by dopaminergic neuron loss in the substantia nigra pars compacta, and complete symptom control can be achieved by dopamine replacement therapy alone, with no involvement of non-dopaminergic systems in disease manifestation.",
      "domain": "neuroscience",
      "expected_R": 0.15,
      "expected_C": 0.1,
      "expected_M": 0.65,
      "expected_X": null,
      "expected_T": 0.2,
      "rationale": "Negative control claim. While nigrostriatal dopamine loss is the primary driver of cardinal motor symptoms, PD involves extensive non-dopaminergic pathology including noradrenergic (locus coeruleus), serotonergic (raphe), and cholinergic (nucleus basalis) system degeneration (Del Tredici and Braak, 2012, Parkinsonism and Related Disorders). Non-motor symptoms (constipation, REM sleep behavior disorder, depression, cognitive impairment) involve non-dopaminergic circuits and are often refractory to dopamine replacement. Levodopa does not prevent disease progression. The 'exclusively' and 'complete symptom control' framing is demonstrably false.",
      "difficulty": "easy"
    },
    {
      "id": "ns_041",
      "claim": "Genome-wide association studies of major depressive disorder have identified over 100 risk loci with small individual effect sizes, implicating synaptic signaling, neuronal excitability, and immune-inflammatory pathways, but explaining less than 10% of the estimated heritability and highlighting the highly polygenic architecture of psychiatric disorders.",
      "domain": "neuroscience",
      "expected_R": 0.8,
      "expected_C": 0.5,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Howard et al. (2019, Nature Neuroscience) identified 102 MDD risk loci in a GWAS of ~800,000 individuals. Wray et al. (2018, Nature Genetics) established polygenic architecture of MDD. Pathway enrichment for synaptic and immune genes is replicated across studies. The 'missing heritability' gap (<10% explained) is a robust finding consistent across psychiatric GWAS. Cross-omics from GWAS, transcriptomic enrichment, and brain eQTL analyses partially converge on implicated pathways. Polygenic risk scores have limited individual predictive value (AUC ~0.55-0.60). Population stratification and phenotype heterogeneity remain challenges.",
      "difficulty": "medium"
    },
    {
      "id": "ns_042",
      "claim": "Repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (DLPFC) is an FDA-cleared treatment for treatment-resistant depression, with high-frequency (10 Hz) protocols and intermittent theta burst stimulation (iTBS) achieving remission rates of 30-35% in patients who have failed adequate pharmacotherapy trials.",
      "domain": "neuroscience",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.75,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "FDA cleared rTMS for treatment-resistant depression in 2008. O'Reardon et al. (2007, Biological Psychiatry) demonstrated efficacy in pivotal trial. THREE-D trial (Blumberger et al., 2018, The Lancet) showed non-inferiority of 3-minute iTBS to standard 37-minute rTMS protocol. SAINT protocol (Cole et al., 2020, American Journal of Psychiatry) achieved ~79% remission with accelerated iTBS, though in a small open-label study. Sham-controlled remission rates of 30-35% are replicated across trials. However, optimal target selection, stimulation parameters, and patient selection criteria are still being refined. Durability of response varies.",
      "difficulty": "easy"
    },
    {
      "id": "ns_043",
      "claim": "Psilocybin and other classic psychedelics (LSD, DMT) produce their consciousness-altering effects primarily through 5-HT2A receptor agonism in cortical layer V pyramidal neurons, and clinical trials have demonstrated rapid and sustained antidepressant effects of psilocybin-assisted therapy in treatment-resistant depression and end-of-life distress.",
      "domain": "neuroscience",
      "expected_R": 0.7,
      "expected_C": 0.4,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "Vollenweider and Kometer (2010, Nature Reviews Neuroscience) reviewed psychedelic pharmacology. 5-HT2A mechanism confirmed by ketanserin blockade studies. Davis et al. (2021, JAMA Psychiatry) and Carhart-Harris et al. (2021, New England Journal of Medicine) demonstrated psilocybin antidepressant effects in RCTs. Griffiths et al. (2016, Journal of Psychopharmacology) showed efficacy in end-of-life distress. However, blinding is difficult in psychedelic trials (expectancy effects). Effect sizes are large but sample sizes are small. The relative contribution of pharmacology vs. psychotherapy vs. mystical experience is debated. Temporal stability is moderate as the field is rapidly expanding.",
      "difficulty": "hard"
    },
    {
      "id": "ns_044",
      "claim": "Epigenetic modifications including DNA methylation and histone acetylation in the hippocampus and prefrontal cortex are dynamically regulated by learning experiences and stress exposure, contributing to long-term memory formation and stress-related psychiatric disorders, with histone deacetylase (HDAC) inhibitors enhancing memory consolidation in animal models.",
      "domain": "neuroscience",
      "expected_R": 0.75,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.6,
      "rationale": "Levenson et al. (2004, Journal of Biological Chemistry) demonstrated learning-induced histone acetylation changes. Miller and Sweatt (2007, Neuron) showed DNA methylation changes during fear conditioning. HDAC inhibitor enhancement of memory consolidation replicated by multiple groups (Stefanko et al., 2009, Proceedings of the National Academy of Sciences). Stress-induced epigenetic changes reviewed by McEwen et al. (2015, Neurobiology of Stress). Cross-omics from ChIP-seq, bisulfite sequencing, and behavioral testing converge. However, human evidence for experience-dependent epigenetic changes in brain is extremely limited (postmortem tissue). Causal vs. correlational relationships are difficult to establish in humans.",
      "difficulty": "hard"
    },
    {
      "id": "ns_045",
      "claim": "Neurofilament light chain (NfL) in blood is a sensitive but non-specific biomarker of neuroaxonal injury, elevated across multiple neurological conditions including Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and traumatic brain injury, with clinical utility for monitoring disease progression and treatment response in MS clinical trials.",
      "domain": "neuroscience",
      "expected_R": 0.85,
      "expected_C": 0.55,
      "expected_M": 0.8,
      "expected_X": null,
      "expected_T": 0.65,
      "rationale": "Khalil et al. (2018, Nature Reviews Neurology) comprehensively reviewed blood NfL across neurological diseases. Disanto et al. (2017, Annals of Neurology) showed NfL predicts disability worsening in MS. NfL incorporated as outcome measure in MS clinical trials (siponimod, ocrelizumab). Simoa platform enables ultrasensitive blood measurement (Kuhle et al., 2019, Neurology). Well-replicated across large cohorts and multiple diseases. The non-specificity limits diagnostic utility but enhances monitoring utility. Age-dependent normative ranges are now established. One of the most successful translational biomarkers in neurology.",
      "difficulty": "medium"
    },
    {
      "id": "ns_046",
      "claim": "The claustrum is the seat of consciousness, functioning as a central hub that integrates information from all cortical regions to generate unified conscious experience, and its selective disruption produces immediate and complete loss of consciousness in all cases.",
      "domain": "neuroscience",
      "expected_R": 0.15,
      "expected_C": 0.1,
      "expected_M": 0.3,
      "expected_X": null,
      "expected_T": 0.2,
      "rationale": "Negative control claim. Crick and Koch (2005, Philosophical Transactions of the Royal Society B) hypothesized the claustrum's role in consciousness based on its connectivity. Koubeissi et al. (2014, Epilepsy and Behavior) reported a single case of consciousness loss with claustrum stimulation. However, this was a single epilepsy patient with extensive brain pathology. The 'seat of consciousness' claim is not supported by systematic evidence. Other claustrum lesion cases do not consistently produce consciousness loss (Chau et al., 2015, Consciousness and Cognition). The claim of 'immediate and complete loss in all cases' is demonstrably false. The claustrum's role in consciousness remains highly speculative.",
      "difficulty": "easy"
    },
    {
      "id": "ns_047",
      "claim": "Spatial transcriptomics of the mouse and human brain reveals that gene expression gradients, rather than discrete boundaries, define many brain region transitions, with continuous molecular gradients across cortical layers and inter-region borders challenging the classical cytoarchitectonic parcellation of Brodmann areas.",
      "domain": "neuroscience",
      "expected_R": 0.7,
      "expected_C": 0.45,
      "expected_M": 0.7,
      "expected_X": null,
      "expected_T": 0.5,
      "rationale": "MERFISH and Visium spatial transcriptomics of mouse brain (Zhang et al., 2023, Science) revealed molecular gradients across brain regions. Maynard et al. (2021, Nature Neuroscience) characterized spatial gene expression in human DLPFC layers. Allen Brain Atlas ISH data supports graded gene expression across cortical areas. However, some brain boundaries are indeed sharp (hippocampal subfield transitions). The claim that gradients 'challenge' Brodmann parcellation is debated — molecular and cytoarchitectonic boundaries partially overlap. Cross-omics from spatial transcriptomics, scRNA-seq, and histology converge. Rapidly evolving field with methodological limitations in resolution.",
      "difficulty": "hard"
    },
    {
      "id": "ns_048",
      "claim": "Non-invasive brain stimulation techniques including transcranial direct current stimulation (tDCS) produce reliable, large-magnitude cognitive enhancement in healthy individuals, improving working memory, attention, and learning by 20-30% through direct modulation of cortical excitability, with effects persisting for weeks after stimulation.",
      "domain": "neuroscience",
      "expected_R": 0.25,
      "expected_C": 0.15,
      "expected_M": 0.55,
      "expected_X": null,
      "expected_T": 0.25,
      "rationale": "Negative control claim. While tDCS can modulate cortical excitability (Nitsche and Paulus, 2000, Journal of Physiology), meta-analyses of cognitive effects show inconsistent and typically small effects (Horvath et al., 2015, Neuropsychologia). Claims of 20-30% improvement are not supported by systematic evidence. Many tDCS cognitive studies suffer from small sample sizes, publication bias, and inconsistent stimulation parameters. Replication failures are common (Medina and Bhatt, 2020, Cortex). Current density modeling shows substantial inter-individual variability due to skull and CSF anatomy. The 'reliable, large-magnitude' framing is an overstatement.",
      "difficulty": "easy"
    },
    {
      "id": "ns_049",
      "claim": "Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for advanced Parkinson's disease motor symptoms, reducing medication requirements and motor fluctuations, though with potential side effects including speech impairment, mood changes, and cognitive effects in a subset of patients.",
      "domain": "neuroscience",
      "expected_R": 0.9,
      "expected_C": 0.5,
      "expected_M": 0.85,
      "expected_X": null,
      "expected_T": 0.8,
      "rationale": "EARLYSTIM trial (Schuepbach et al., 2013, New England Journal of Medicine) and multiple prior RCTs (Deuschl et al., 2006, New England Journal of Medicine) established STN-DBS efficacy. Motor improvement of 40-60% on UPDRS-III in medication-off state is well-replicated across centers worldwide. Levodopa equivalent dose reduction of 50-60% is consistent. Speech deterioration occurs in 10-15% of patients. Cognitive and psychiatric side effects are documented but variable. Patient selection criteria are well-defined. One of the most successful neuromodulation therapies with 20+ years of clinical data and consistent outcomes across countries.",
      "difficulty": "easy"
    },
    {
      "id": "ns_050",
      "claim": "The monoamine hypothesis of depression, which posits that depression is caused by a simple deficit in serotonin, norepinephrine, or dopamine levels in the synaptic cleft, fully explains the pathophysiology of major depressive disorder and accounts for all treatment responses and non-responses to antidepressant medications.",
      "domain": "neuroscience",
      "expected_R": 0.15,
      "expected_C": 0.1,
      "expected_M": 0.35,
      "expected_X": null,
      "expected_T": 0.2,
      "rationale": "Negative control claim. The monoamine hypothesis in its simple form is widely considered insufficient (Coppen, 1967, British Journal of Psychiatry introduced the serotonin hypothesis, but it has been extensively revised). Moncrieff et al. (2022, Molecular Psychiatry) comprehensively reviewed evidence against the simple serotonin deficiency model. No consistent evidence shows reduced serotonin levels in depressed patients. Rapid tryptophan depletion does not reliably induce depression in unmedicated individuals. Ketamine (NMDA antagonist) and psilocybin (5-HT2A agonist) have antidepressant effects through non-monoamine mechanisms. The 'fully explains' and 'accounts for all' framing is demonstrably false. Depression pathophysiology involves neuroplasticity, neuroinflammation, HPA axis, gut-brain axis, and circuit-level dysfunction beyond monoamines.",
      "difficulty": "easy"
    }
  ]
}